HTTP 200 OK
Allow: GET, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept
{
"count": 1453,
"next": "https://mitotox.org/api/compounds/list?format=api&page=14",
"previous": "https://mitotox.org/api/compounds/list?format=api&page=12",
"results": [
{
"compound_ID": "D1228",
"name": "Bis((1E)-2-phenylvinyl)phosphinic acid",
"synonyms": "Bis(2-phenylvinyl)phosphinic acid; Oprea1_843021; SCHEMBL9815253; HMS1578G16; ZINC235106; AKOS001033890; bis((1E)-2-phenylvinyl)phosphinic acid; ST50979340;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C16H15O2P",
"molecular_weight": "270.26",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "787101",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01553"
]
},
{
"compound_ID": "D1229",
"name": "1-[2-(Allyloxy)benzyl]-4-benzylpiperidine",
"synonyms": "Oprea1_779800; MLS000974548; CHEMBL1483212; HMS2840E13; ZINC2464008; MCULE-8665455223; SMR000496395; 1-[2-(allyloxy)benzyl]-4-benzylpiperidine;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C22H27NO",
"molecular_weight": "321.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "2053518",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01554"
]
},
{
"compound_ID": "D1230",
"name": "2,5-Diaminoterephthalic acid",
"synonyms": "2,5-diaminoterephthalic acid; 945-30-2; 2,5-diaminobenzene-1,4-dicarboxylic acid; 1,4-Benzenedicarboxylic acid, 2,5-diamino-; 2,5-DIAMINOTEREPHTHALICACID; ACMC-20aobh; Cambridge id 5180162; Oprea1_205111; Oprea1_216725; CBDivE_006536; SCHEMBL987442; CTK3G9221; DTXSID20355701; ZINC330106; ACN-P001076; FCH835597; STK036387; AKOS000541081; MCULE-2871607641; ML01047; AS-59320; DA-16740; AX8221961; TC-171188; CS-0110720; FT-0736091; ST50229678; 2,5-Diaminoterephthalic acid, >=95% (HPLC);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C8H8N2O4",
"molecular_weight": "196.16",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "816761",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01555"
]
},
{
"compound_ID": "D1231",
"name": "N-(1-Adamantylcarbonyl)-N'-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)thiourea",
"synonyms": "Oprea1_830622; ZINC4321571; STK329027; AKOS005438000; MCULE-7274149162; AG-690/34158016; N-(1-adamantylcarbonyl)-N'-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)thiourea; 412964-20-6; N-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamothioyl]tricyclo[3.3.1.1~3,7~]decane-1-carboxamide;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C21H25N3OS2",
"molecular_weight": "399.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "2830758",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01556"
]
},
{
"compound_ID": "D1232",
"name": "2-(Isobutylthio)succinic acid",
"synonyms": "2-(isobutylthio)succinic acid; 2-[(2-methylpropyl)sulfanyl]butanedioic acid; CBDivE_003448; Cambridge id 5152843; STK531081; AKOS001645690; CCG-110962; MCULE-5025540855; AB00074583-01;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C8H14O4S",
"molecular_weight": "206.26",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "2830878",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01557"
]
},
{
"compound_ID": "D1233",
"name": "N-{4-[Acetyl(methyl)amino]phenyl}-4-biphenylcarboxamide",
"synonyms": "N-{4-[acetyl(methyl)amino]phenyl}-4-biphenylcarboxamide; Cambridge id 5191683; Oprea1_485405; Oprea1_563850; ARONIS017109; KS-000049LX; ZINC2472236; STK089993; AKOS000482987; MCULE-8346367144; AB00075093-01; AN-329/10003008; N-{4-[acetyl(methyl)amino]phenyl}biphenyl-4-carboxamide; N-{4-[acetyl(methyl)amino]phenyl}[1,1'-biphenyl]-4-carboxamide;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C22H20N2O2",
"molecular_weight": "344.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "2054616",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01558"
]
},
{
"compound_ID": "D1234",
"name": "4-[(E)-3-(2-Ethylpiperidin-1-yl)prop-1-enyl]-N,N-dimethylaniline",
"synonyms": "Cambridge id 5429735; SCHEMBL15702622;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C18H28N2",
"molecular_weight": "272.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5333505",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01559"
]
},
{
"compound_ID": "D1235",
"name": "3-(2-Chloro-phenyl)-2-(4-(2-oxo-2H-chromen-3-YL)-thiazol-2-YL)-acrylonitrile",
"synonyms": "C21H11ClN2O2S; 3-(2-CHLORO-PHENYL)-2-(4-(2-OXO-2H-CHROMEN-3-YL)-THIAZOL-2-YL)-ACRYLONITRILE; ZINC3995819; STK870495; AKOS001142783; AB00075368-01; (2E)-3-(2-chlorophenyl)-2-[4-(2-oxo-2H-chromen-3-yl)-1,3-thiazol-2-yl]prop-2-enenitrile; 333769-55-4;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C21H11ClN2O2S",
"molecular_weight": "390.8",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5331268",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01560"
]
},
{
"compound_ID": "D1236",
"name": "Ethyl (7Z)-2-amino-7-(hydroxyimino)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate",
"synonyms": "ethyl (7Z)-2-amino-7-(hydroxyimino)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate; 352553-46-9; SCHEMBL17378590; BBL001889; STK279738; ZINC13941922; AKOS005426227; VS-00917; T8742; AB00074202-01; SR-01000196401; SR-01000196401-1;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C11H14N2O3S",
"molecular_weight": "254.31",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5403172",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01561"
]
},
{
"compound_ID": "D1237",
"name": "2-Amino-4-(3,4-dichlorophenyl)thiazole",
"synonyms": "39893-80-6; 4-(3,4-dichlorophenyl)thiazol-2-amine; 2-Amino-4-(3,4-dichlorophenyl)thiazole; 4-(3,4-Dichlorophenyl)-1,3-thiazol-2-amine; 4-(3,4-Dichloro-phenyl)-thiazol-2-ylamine; 4-(3,4-dichlorophenyl)-2-thiazolamine; 2-Thiazolamine, 4-(3,4-dichlorophenyl)-; UWAXMUSNRIUHRQ-UHFFFAOYSA-N; 4-(3,4-dichlorophenyl)-1,3-thiazole-2-ylamine; Enamine_005013; Cambridge id 5690819; Oprea1_669576; SCHEMBL474314; CTK4I2062; ZINC35892; DTXSID20347166; HMS1408D19; ALBB-001541; KS-00000A4K; ANW-51901; BBL013902; SBB000846; STK299263; STL301459; AKOS000112486; AKOS022133853; CS-W002632; EBD2223706; MCULE-9516163566; TRA0038791; IDI1_007600; 2-Thiazolamine,4-(3,4-dichlorophenyl)-; 4-(3,4-dichlorophenyl)-thiazol-2-amine; AK-39998; DS-13187; ST005693; SY012599; AB0024705; DB-069890; ST2417956; TR-015917; 4CH-015670; AM20050323; BB 0237384; FT-0678496; Thiazol-2-amine, 4-(3,4-dichlorophenyl)-; W6027; M-9028; AB00093667-01; 4-(3,4-Dichlorophenyl)-1,3-thiazol-2-amine #; A824792; 4-(3,4-dichlorophenyl)-1,3-thiazol-2(3H)-imine; F0016-0216; F1386-0380;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C9H6Cl2N2S",
"molecular_weight": "245.13",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "618536",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01562"
]
},
{
"compound_ID": "D1238",
"name": "5-(2-Nitrobenzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione",
"synonyms": "5-(2-Nitrobenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione; 5-(2-nitrobenzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; CBDivE_011239; CHEMBL4172998; ZINC325153; STK156800; 5-(2-nitrobenzylidene)thiobarbiturate; AKOS000671114; MCULE-3229844389; ST50745428; 5-[(2-nitrophenyl)methylene]-2-thioxo-1,3-dihydropyrimidine-4,6-dione;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C11H7N3O4S",
"molecular_weight": "277.26",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "813003",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01563"
]
},
{
"compound_ID": "D1239",
"name": "3-(4-Bromo-2-thienyl)-2-cyano-2-propenethioamide",
"synonyms": "(2Z)-2-(aminothioxomethyl)-3-(4-bromo(2-thienyl))prop-2-enenitrile; ZINC32223241; AKOS000668628; FCH3278717; FCH3434446; BBV-71547720; ST020711; AB00074978-01; AG-690/36878058; 3-(4-bromo-2-thienyl)-2-cyano-2-propenethioamide;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C8H5BrN2S2",
"molecular_weight": "273.2",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "679235",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01564"
]
},
{
"compound_ID": "D1240",
"name": "Benzyl [(6-amino-3,5-dicyano-4-ethylpyridin-2-yl)sulfanyl]acetate",
"synonyms": "Benzyl [(6-amino-3,5-dicyano-4-ethyl-2-pyridinyl)thio]acetate; SMR000102998; MLS000106027; CHEMBL1529042; HMS1578C15; HMS2413D04; STK837908; ZINC19337959; AKOS005624562; MCULE-2017934268; AB00075382-01; SR-01000198675; SR-01000198675-1; benzyl [(6-amino-3,5-dicyano-4-ethylpyridin-2-yl)sulfanyl]acetate; 184530-24-3;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C18H16N4O2S",
"molecular_weight": "352.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "1067782",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01565"
]
},
{
"compound_ID": "D1241",
"name": "N-{2-[(1,3-Diphenyl-1H-pyrazol-5-yl)amino]phenyl}benzamide",
"synonyms": "N-{2-[(1,3-diphenyl-1H-pyrazol-5-yl)amino]phenyl}benzamide; N-[2-[(1,3-Diphenyl-1H-pyrazol-5-yl)amino]phenyl]benzamide; Oprea1_112740; Oprea1_632011; CBDivE_009693; SCHEMBL14132972; ZINC2473143; AKOS000520538; MCULE-3199729684; ST50225031; BRD-K46268007-001-01-5; N-{2-[(1,3-diphenylpyrazol-5-yl)amino]phenyl}benzamide;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C28H22N4O",
"molecular_weight": "430.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "2054834",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01566"
]
},
{
"compound_ID": "D1242",
"name": "2-Butyl-5-methylisophthalic acid",
"synonyms": "2-Butyl-5-methylisophthalic acid; CBDivE_001229; Cambridge id 5119061; Oprea1_168911; Oprea1_529194; 2-n-butyl-5-methylisophthalic acid; ZINC2464511; MCULE-5885165671; AB00074141-01; SR-01000196216; SR-01000196216-1;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C13H16O4",
"molecular_weight": "236.26",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "2053711",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01567"
]
},
{
"compound_ID": "D1243",
"name": "2-Butylsulfanyl-6-methyl-9H-1,3,4,9-tetraaza-fluorene",
"synonyms": "Cambridge id 5225633; 2-Butylsulfanyl-6-methyl-9H-1,3,4,9-tetraaza-fluorene; ZINC2981613; STK508872; AKOS000362361; CCG-113068; MCULE-2877279180; AB00075849-01; 3-(butylsulfanyl)-8-methyl-5H-[1,2,4]triazino[5,6-b]indole;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C14H16N4S",
"molecular_weight": "272.37",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "6408685",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01568"
]
},
{
"compound_ID": "D1244",
"name": "2-Phenyldipyrrolo[1,2-a:2',1'-c]pyrazine",
"synonyms": "2-Phenyldipyrrolo[1,2-a:2',1'-c]pyrazine; CBDivE_000195; ZINC270673; AKOS000528680; MCULE-8277394992;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C16H12N2",
"molecular_weight": "232.28",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "778628",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01569"
]
},
{
"compound_ID": "D1245",
"name": "BMS 753",
"synonyms": "BMS753; BMS 753; 215307-86-1; BMS-753; GTPL2650; SCHEMBL7212759; BDBM36810; ZINC34008167; AKOS024457647; NCGC00370863-01; BMS 753, >=98% (HPLC); J-014135; Q27075366; 4-[(1,1,3,3-tetramethyl-2-oxoindene-5-carbonyl)amino]benzoic acid; 4-[[(2,3-Dihydro-1,1,3,3-tetramethyl-2-oxo-1H-inden-5-yl)carbonyl]amino]-benzoic acid; 4-[[(2,3-Dihydro-1,1,3,3-tetramethyl-2-oxo-1H-inden-5-yl)carbonyl]amino]benzoic acid",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C21H21NO4",
"molecular_weight": "351.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "9884820",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F02010203"
],
"references": [
"RC01293",
"RC01307"
]
},
{
"compound_ID": "D1246",
"name": "BMS 614",
"synonyms": "BMS614; BMS 195614; BMS 614; BMS-614; 253310-42-8; 182135-66-6; 4-[[[5,6-dihydro-5,5-dimethyl-8-(3-quinolinyl)-2-naphthalenyl]carbonyl]amino]benzoic acid; 4-(5,5-Dimethyl-8-(quinolin-3-yl)-5,6-dihydronaphthalene-2-carboxamido)benzoic acid; BMS195614; BMS-195614; GTPL2643; SCHEMBL6756065; CHEMBL2385269; BDBM36811; CHEBI:132571; ZINC1893319; AKOS024457734; API0010288; CID:445091; 4-[(5,5-dimethyl-8-quinolin-3-yl-6H-naphthalene-2-carbonyl)amino]benzoic acid; NCGC00370906-01; BMS-195614, >=97% (HPLC); J-015939; Q27075359; 4-[(5,5-dimethyl-8-quinolin-3-yl6H-naphthalene-2-carbonyl)amino]benzoic acid; 4-[[[5,6-dihydro-5,5-dimethyl-8-(3-quinolinyl)-2-naphthalenyl]carbonyl]amino]-benzoicacid; 4-({[5,5-dimethyl-8-(quinolin-3-yl)-5,6-dihydronaphthalen-2-yl]carbonyl}amino)benzoic acid",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C29H24N2O3",
"molecular_weight": "448.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "445091",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F02010203"
],
"references": [
"RC01294",
"RC01308"
]
},
{
"compound_ID": "D1247",
"name": "BMS 961",
"synonyms": "BMS 961; 185629-22-5; SCHEMBL165751; CHEMBL4216904; CTK7J6336; 3-Fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-2-naphthalenyl)acetyl]amino]-benzoic acid; AKOS024457614; API0010279; BMS 189961; J-011906; 3-fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino]benzoic acid; 3-Fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acetylamino]-benzoic acid; 3-fluoro-4-{[hydroxy(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)acetyl]amino}benzoic acid; BENZOIC ACID, 3-FLUORO-4-[[(2R)-HYDROXY(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)ACETYL]AMINO]-",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C23H26FNO4",
"molecular_weight": "399.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "2418",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F02010203"
],
"references": [
"RC01295",
"RC01309"
]
},
{
"compound_ID": "D1248",
"name": "CD 2665",
"synonyms": "CD 2665; CD2665; 170355-78-9; CD-2665; 4-[6-[(2-Methoxyethoxy)methoxy]-7-tricyclo[3.3.1.13,7]dec-1-yl-2-naphthalenyl)benzoic acid; JBALRFFXKQPVLT-UHFFFAOYSA-N; GTPL2654; SCHEMBL1361023; SCHEMBL14377478; CTK4D3563; DTXSID50168846; ZINC31597129; 4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic acid; AKOS024457807; 4-(6-((2-Methoxyethoxy)methoxy)-7-tricyclo(3.3.1.1.3,7)dec-1-yl-2-naphthalenyl)Benzoic acid; HY-107437; RT-011948; B7501; CS-0028470; J-010615; Q27075801; 4-[7-(1-adamantyl)-6-methoxyethoxymethoxy-2-naphthyl]benzoic acid; 4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic a cid; Benzoic acid, 4-(6-((2-methoxyethoxy)methoxy)-7-tricyclo(3.3.1.1.3,7)dec-1-yl-2-naphthalenyl)-; Benzoic acid,4-[6-[(2-methoxyethoxy)methoxy]-7-tricyclo[3.3.1.13,7]dec-1-yl-2-naphthalenyl]-",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C31H34O5",
"molecular_weight": "486.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "216241",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F02010203"
],
"references": [
"RC01296",
"RC01310"
]
},
{
"compound_ID": "D1249",
"name": "HU 308",
"synonyms": "HU 308; CHEMBL2179724; 256934-39-1; HU-308; HU308; ((1R,2R,5R)-2-(2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl)-7,7-dimethyl-4-bicyclo(3.1.1)hept-3-enyl) methanol; SCHEMBL14440176; CHEBI:146244; ZINC3981939; BDBM50399157; AKOS024457418; FT-0669246; (+)-{(1S,4S,5S)-4-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl}methanol; {(1S,4S,5S)-4-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl}methanol; 4-[4-(1,1-Dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethylbicyclo[3.1.1]hept-2-ene-2-methanol",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C27H42O3",
"molecular_weight": "414.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "11553430",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F02010203"
],
"references": [
"RC01302",
"RC01316"
]
},
{
"compound_ID": "D1250",
"name": "fenazaquin",
"synonyms": "Fenazaquin; 120928-09-8; 4-(4-(tert-Butyl)phenethoxy)quinazoline; Fenazaquin [ISO]; 4-[2-(4-tert-butylphenyl)ethoxy]quinazoline; 4-tert-Butylphenethylquinazolin-4-yl ether; UNII-DK5Q534WEE; DK5Q534WEE; CHEBI:38593; DMYHGDXADUDKCQ-UHFFFAOYSA-N; 4-((4-(1,1-Dimethylethyl)phenyl)ethoxy)quinazoline; Quinazoline, 4-((4-(1,1-dimethylethyl)phenyl)ethoxy)-; Quinazoline, 4-[2-[4-(1,1-dimethylethyl)phenyl]ethoxy]-; Fenazachin; Fenaza; Magus; Pride Ultra; Quinazoline, 4-(2-(4-(1,1-dimethylethyl)phenyl)ethoxy)-; Fenazaquine; HSDB 7948; XDE 436; GWN 1708; EL 436; EC 410-580-0; DSSTox_CID_20476; DSSTox_RID_79499; DSSTox_GSID_40476; SCHEMBL26216; CHEMBL243282; DTXSID4040476; ZINC2383010; Tox21_301223; 4-(4-tert-butylphenethoxy)quinazoline; AKOS015903772; KS-5370; Fenazaquin 10 microg/mL in Cyclohexane; KS-00000G96; Fenazaquin 10 microg/mL in Acetonitrile; Fenazaquin 100 microg/mL in Cyclohexane; NCGC00255594-01; Fenazaquin 100 microg/mL in Acetonitrile; SC-19723; DB-041590; LS-140102; CAS-120928-09-8; FT-0631103; 4-[2-[4-(t-Butyl)phenyl]ethoxy]quinazoline; Fenazaquin, PESTANAL(R), analytical standard; C18727; 31411-EP2274983A1; 31411-EP2275422A1; 31411-EP2292608A1; 31411-EP2308857A1; 31411-EP2308858A1; 31411-EP2311816A1; 31411-EP2311817A1; 928F098; J-004412; Q1404580; 4-(2-(4-(1,1-Dimethylethyl)phenyl)ethoxy)quinazoline; 4-{2-[4-(2-Methyl-2-propanyl)phenyl]ethoxy}quinazoline",
"trade_name": "",
"abbrev_name": "",
"description": "quinazoline; pesticide",
"molecular_formula": "C20H22N2O",
"molecular_weight": "306.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "86356",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103",
"F020403"
],
"references": [
"RC01380",
"RC04930"
]
},
{
"compound_ID": "D1251",
"name": "6-chloro-benzothiadiazole",
"synonyms": "6-Chloro-1,2,3-benzothiadiazole; 23644-01-1; 1,2,3-Benzothiadiazole, 6-chloro-; 6-Chlorobenzo[d][1,2,3]thiadiazole; 3-chloro-9-thia-7,8-diazabicyclo[4.3.0]nona-2,4,7,10-tetraene; 1,2,3-BENZOTHIADIAZOLE,6-CHLORO-; SCHEMBL10630197; CTK4F1969; DTXSID60178315; ZINC6094078; FCH856897; AKOS006285653; ACM23644011",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C6H3ClN2S",
"molecular_weight": "170.62",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "185548",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01383"
]
},
{
"compound_ID": "D1252",
"name": "pterulone",
"synonyms": "pterulone; (Z)-Pterulone; CHEMBL450490; SCHEMBL6107143; Q7256974",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C13H11ClO2",
"molecular_weight": "234.68",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "11424846",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01366"
]
},
{
"compound_ID": "D1253",
"name": "2-methylharmine",
"synonyms": "2-Methyl Harmine; 7-methoxy-1,2-dimethyl-9H-pyrido[3,4-b]indol-2-ium; CHEMBL1178810; CTK8F4391; ZINC6521032; AKOS030213256; FT-0671805; J-013942; 9H-Pyrido[3,4-b]indolium, 7-methoxy-1,2-dimethyl-",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C14H15N2O+",
"molecular_weight": "227.28",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "486626",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01392"
]
},
{
"compound_ID": "D1254",
"name": "TIQ",
"synonyms": "BRN 0425810; TIQ; trans-6-Acetamido-2,3-dimethyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline; Isoquinoline, 6-acetamido-2,3-dimethyl-4-phenyl-1,2,3,4-tetrahydro-, (E)-; N-(trans-1,2,3,4-Tetrahydro-2,3-dimethyl-4-phenyl-6-isoquinolinyl)acetamide; Acetamide, N-(trans-1,2,3,4-tetrahydro-2,3-dimethyl-4-phenyl-6-isoquinolinyl)-; ISOQUINOLINE, 1,2,3,4-TETRAHYDRO-6-ACETAMIDO-2,3-DIMETHYL-4-PHENYL-, (E)-; 41958-62-7; DTXSID20962111; LS-85793; N-(2,3-Dimethyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-6-yl)ethanimidic acid",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C19H22N2O",
"molecular_weight": "294.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "39062",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01393"
]
},
{
"compound_ID": "D1255",
"name": "HPP+",
"synonyms": "haloperidol pyridinium; UNII-47Z7A2W953; 47Z7A2W953; 4-Cfobp; Bcpp(+); Hpp(+); CHEMBL1269; SCHEMBL13385512; 4-(4-Chlorophenyl)-1-(4-(fluorophenyl)-4-oxobutyl)pyridium; 4-(4-Chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)pyridinium; Q27259091; Pyridium, 4-(4-chlorophenyl)-1-(4-(fluorophenyl)-4-oxobutyl)-; 4-(4-Chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-pyridinium (HPP+)",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C21H18ClFNO+",
"molecular_weight": "354.8",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "9975463",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01396"
]
},
{
"compound_ID": "D1256",
"name": "Dequalinium Chloride",
"synonyms": "dequalinium chloride; 522-51-0; Dequalinium Dichloride; Dequafungan; Danical; Decabis; Decaminum; Decosan; Dekuarin; Eriosept; Erosept; Gorgine; Grocreme; Optipect; Phylletten; Angils; Efisol; Evazol; Vaster; Dequalinii chloridum; Decamine; Dekadin; Dekamin; Dequadin; Dequavagyn; Dequavet; Labosept; Oralgol; Polycidine; Rumilet; Sanoral; Sentril; Cloruro de decalinio; Ivazil; Sorot; BAQD 10; Dequalin chloride; Chlorure de dequalinium; Dequalinium (Chloride); Dequalinum Chloride; Dynexan-mhp; Decamine (pharmaceutical); UNII-XYS8INN1I6; Dequalinio cloruro [DCIT]; 1,1'-Decamethylenebis(4-aminoquinaldinium chloride); Dequalinii chloridum [INN-Latin]; Dequalinium chloride hydrate; Decamethylenebis(4-aminoquinaldinium chloride); Cloruro de decalinio [INN-Spanish]; EINECS 208-330-9; Dequalinium chloride [INN:BAN:JAN]; XYS8INN1I6; Chlorure de dequalinium [INN-French]; NSC 166454; CHEBI:31466; 1,10-Decamethylene-bis(4-aminoquinaldinium chloride); Quinaldinium, 1,1'-decamethylenebis(4-amino)-, dichloride; 1,1'-(1,10-Decanediyl)bis(4-amino-2-methylquinolinium) dichloride; Quinolinium, 1,1'-(1,10-decanediyl)bis[4-amino-2-methyl-, dichloride; W-105841; Quinaldinium, 1,1'-decamethylenebis(4-amino-, dichloride; Quinolinium, 1,1'-(1,10-decanediyl)bis(4-amino-2-methyl-, dichloride; CHEMBL121663; Dequalinio cloruro; 1-[10-(4-amino-2-methylquinolin-1-ium-1-yl)decyl]-2-methylquinolin-1-ium-4-amine;dichloride; C30H40N4; NSC-166454; SR-01000075814; NCGC00015339-02; CAS-522-51-0; C30H40Cl2N4; Nordman (TN); DSSTox_CID_25144; DSSTox_RID_80700; DSSTox_GSID_45144; SCHEMBL34043; BAQD-10; SPECTRUM1503127; DTXSID3045144; CTK8F9037; Dequalinium chloride (JAN/INN); HMS502F14; HMS1569M17; HMS1922G11; HMS2096M17; HMS3261C17; HMS3713M17; BCP21273; HY-B0567; Tox21_110128; Tox21_500338; BN0180; s4066; AKOS015895242; API0014417; CCG-213734; CS-2676; LP00338; MCULE-5255183860; 1,1 inverted exclamation marka-Decamethylenebis(4-aminoquinaldinium) dichloride; NCGC00093777-01; NCGC00093777-02; NCGC00093777-03; NCGC00261023-01; CC-26341; SC-22665; AB1003158; DB-052103; LS-139898; EU-0100338; FT-0603110; ST50981059; D 3768; D01575; C-23091; Q5261117; SR-01000075814-1; SR-01000075814-3; SR-01000075814-6; SR-01000075814-7; 1,1'-Decamethylenebis(4-aminoquinaldinium) dichloride; 1,1'-DECAMETHYLENEBIS(4-AMINOQUINALDINIUM CHLORIDE; 1,1'-(decane-1,10-diyl)bis(4-amino-2-methylquinolinium) chloride; 1,1'-decane-1,10-diylbis(4-amino-2-methylquinolinium) dichloride; DECA; Dequavagyn; NSC 166454; NSC-166454; NSC166454; Dequalinium chloride, European Pharmacopoeia (EP) Reference Standard; 1-[10-(4-amino-2-methylquinolyl)decyl]-2-methyl-4-quinolylamine, chloride, chl oride; Dequalinium chloride for performance test, European Pharmacopoeia (EP) Reference Standard; Dequalinium chloride, Pharmaceutical Secondary Standard; Certified Reference Material; Quinolinium, 1,1'-(1,10-decanediyl)bis(4-amino-2-methyl-, dichloride (9CI); quinolinium, 1,1'-(1,10-decanediyl)bis[4-amino-2-methyl-, chloride (1:2)",
"trade_name": "",
"abbrev_name": "",
"description": "quaternary ammonium cation and bolaamphiphile; antiseptic and disinfectant;",
"molecular_formula": "C30H40Cl2N4",
"molecular_weight": "527.6",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "The degree of absorption is minimal in case of topical or vaginal administration thus systemic exposure is negligible. <0.1 % is absorbed systemically after oral administration.",
"cid": "10649",
"classification": "D; G; R",
"indications": "",
"side_effects": "",
"atc_codes": "R02AA02; D08AH01; G01AC05",
"group": "Drug",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F01",
"F020103",
"F0504",
"F060105",
"F0701"
],
"references": [
"RC01397",
"RC03923",
"RC03924",
"RC03926",
"RC03928"
]
},
{
"compound_ID": "D1257",
"name": "Catechol",
"synonyms": "pyrocatechol; catechol; 120-80-9; 1,2-dihydroxybenzene; 1,2-benzenediol; benzene-1,2-diol; pyrocatechin; 2-hydroxyphenol; o-Benzenediol; o-Dihydroxybenzene; Pyrocatechine; o-Dioxybenzene; o-Hydroquinone; o-Hydroxyphenol; o-Phenylenediol; Oxyphenic acid; Phthalhydroquinone; Fouramine PCH; benzenediol; Durafur developer C; Pelagol Grey C; Catechin (phenol); Fourrine 68; Benzene, o-dihydroxy-; Catechol (phenol); o-Diphenol; ortho-Hydroxyphenol; Pyrokatechin; Pyrokatechol; Katechol; ortho-Dihydroxybenzene; C.I. Oxidation Base 26; ortho-Benzenediol; ortho-Dioxybenzene; ortho-Hydroquinone; Katechol [Czech]; ortho-Phenylenediol; Pyrocatechinic acid; NCI-C55856; Pyrokatechin [Czech]; Pyrokatechol [Czech]; CI Oxidation Base 26; UNII-LF3AJ089DQ; NSC 1573; C.I. 76500; CCRIS 741; Catechol-pyrocatechol; HSDB 1436; YCIMNLLNPGFGHC-UHFFFAOYSA-N; EINECS 204-427-5; BRN 0471401; LF3AJ089DQ; CI 76500; AI3-03995; CHEMBL280998; DTXSID3020257; CHEBI:18135; MFCD00002188; 12385-08-9; CAQ; Catechol, 99+%; DSSTox_CID_257; DSSTox_RID_75468; DSSTox_GSID_20257; Phthalic alcohol; CAS-120-80-9; SMR000326660; Benzcatechin; Oxyphenate; Kachin; ortho-diphenol; benzene diol; ortho-Quinol; o Dihydroxybenzene; 4oow; alpha-hydroxyphenol; 1,2-benzenedio; o-dihydroxy-benzene; phenol derivative, 2; 3fw4; 4k7i; ACMC-1BTYG; Pyrocatechol, >=99%; Lopac-C-9510; WLN: QR BQ; bmse000385; EC 204-427-5; 1,2-Dihydroxybenzene, XI; 1,2-Benzenediol; Catechol; Lopac0_000280; SCHEMBL18351; KSC177E7T; MLS002153385; MLS002303022; BIDD:ER0327; Pyrocatechinic acidPyrocatechol; Pyrocatechol, p.a., 99.0%; BDBM26188; CTK0H7279; Durafur Developer CFouramine PCH; NSC1573; Benzene-1,2-diol (Pyrocatechol); HMS2233A17; HMS3260H22; HMS3373K16; KS-000000NB; NSC-1573; Tox21_202317; Tox21_300153; Tox21_500280; ANW-17534; BBL002408; LS-637; s6305; SBB040792; STK398651; ZINC13512214; AKOS000119002; CCG-204375; DB02232; LP00280; MCULE-9007211544; RTR-003436; SDCCGSBI-0050268.P002; TRA0043461; Catechol 100 microg/mL in Acetonitrile; NCGC00015283-01; NCGC00015283-02; NCGC00015283-03; NCGC00015283-04; NCGC00015283-05; NCGC00015283-06; NCGC00015283-07; NCGC00015283-08; NCGC00091262-01; NCGC00091262-02; NCGC00091262-03; NCGC00253952-01; NCGC00259866-01; NCGC00260965-01; BP-21156; SC-19023; AB1002105; Catechol (Pyrocatechol; Benzene-1,2-diol); DB-003770; ST2407554; TR-003436; EU-0100280; FT-0606411; P0317; P0567; ST50214346; T7344; Pyrocatechol; 1,2-Dihydroxybenzene; Catechol; 3437-EP2298767A1; 3437-EP2301934A1; 3437-EP2305633A1; 3437-EP2314587A1; C 9510; C00090; C01785; C15571; 1,2-Dihydroxybenzene, ReagentPlus(R), >=99%; 28696-EP2314579A1; Pyrocatechol, purified by sublimation, >=99.5%; A804599; AB-131/40235236; Q282440; SR-01000075791; SR-01000075791-1; W-109068; F0001-0332; Pyrocatechol, certified reference material, TraceCERT(R); Z1262246103; InChI=1/C6H6O2/c7-5-3-1-2-4-6(5)8/h1-4,7-8; Pyrocatechol, plant cell culture tested, BioReagent, >=99%, powder; 2H-1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-,(2R-trans)-; 19481-10-8",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C6H6O2",
"molecular_weight": "110.11",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "289",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01402"
]
},
{
"compound_ID": "D1258",
"name": "Erythrosin 5'-iodoacetamide",
"synonyms": "86583-16-6; Iodoacetamidoerythrosin; Erythrosine-5'-iodoacetamide; DTXSID201006944; Acetamide, N-(3',6'-dihydroxy-2',4',5',7'-tetraiodo-3-oxospiro(isobenzofuran-1(3H),9'-(9H)xanthen)-5-yl)-2-iodo-; N-(3',6'-Dihydroxy-2',4',5',7'-tetraiodo-3-oxo-3H-spiro[2-benzofuran-1,9'-xanthen]-5-yl)-2-iodoethanimidic acid",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C22H10I5NO6",
"molecular_weight": "1018.8",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "135773",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01410"
]
},
{
"compound_ID": "D1259",
"name": "Safranine",
"synonyms": "BASIC RED 2; 477-73-6; Safranine O; Safranine T; Safranin T; Gossypimine; Safranin; Safranin O; Safranine; 3,7-Diamino-2,8-dimethyl-5-phenylphenazin-5-ium chloride; C.I. Basic Red 2; Tolusafranine; Hidaco safranine; Safranine Zh; Safranine A; Safranine B; Safranine G; Safranine J; Safranine Y; Safranine GF; Safranine OK; Safranine TH; Safranine TN; Safranine TS; Safranine YN; Calcozine Red Y; Leather Red HT; Mitsui safranine T; Brilliant safranine G; Safranine Superfine G; Brilliant safranine BR; Brilliant safranine GR; Mitsui safranine; Cotton Red; Nippon kagaku safranine T; 2,8-Dimethylphenosafranine; Nippon kagaku safranine GK; UNII-XTX0YXU2HV; C.I. 50240; Cerven zasadita 2 [Czech]; C20H19N4.Cl; Phenazinium, 3,7-diamino-2,8-dimethyl-5-phenyl-, chloride; CCRIS 1215; CI 50240; HSDB 2723; 3,7-Diamino-2,8-dimethyl-5-phenylphenazinium chloride; XTX0YXU2HV; EINECS 207-518-8; NSC 47719; Safranine O (C.I. 50240); MFCD00011759; S-0700; 3,7-Diamino-2,8-dimethyl-5-phenazinium chloride; Phenazinium, 3,7-diamino-2,8-dimethyl-5-phenyl-, chloride (1:1); Safranine O, 85%, pure, certified; Safranin A; Safranin Y; Cerven zasadita 2; Safranine O, 95%, pure, high purity biological stain; Safranin Y or A; Safarin T Solution; Safranin O Solution; Gram's safranin solution; SCHEMBL15265; Safranine O, Technical grade; C.I. Basic Red 2 (8CI); DTXSID60874047; OARRHUQTFTUEOS-UHFFFAOYSA-N; 3,7-dimethyl-10-phenylphenazin-10-ium-2,8-diamine;chloride; 477-73-6 (comp.); KS-00000YD2; NSC47719; Safranin O, Dye content >=85 %; Gram-Hucker's stain solution (III); GT4125; NSC-47719; AKOS000283004; DYE0000338; MCULE-6492536721; Gram's safranin solution, for microscopy; AK121908; AS-17149; ST009480; T309; AX8150735; LS-103029; FT-0690012; S0145; ST24028241; BASIC DYE (SAFRANINE B C.I. 50200); C19919; J90023; Q413672; 3,7-diamino-2,8-dimethyl-5-phenyl-phenazinium chloride; 3,7-dimethyl-10-phenylphenazine-2,8-diamine, chloride; Phenazinium,7-diamino-2,8-dimethyl-5-phenyl-, chloride; Safranin O, certified by the Biological Stain Commission; Safranin O, for microscopy (Bact., Bot., Hist.), indicator (pH 0.3-1.0)",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C20H19ClN4",
"molecular_weight": "350.8",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "2723800",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01411"
]
},
{
"compound_ID": "D1260",
"name": "dioc5(3)",
"synonyms": "3,3'-Dipentyloxacarbocyanine; 3,3'-dipentyl-2,2'-oxacarbocyanine; DiOC5(3); 60031-82-5; Dioc(5)(3); SCHEMBL10036118; CHEBI:86288; AKOS000814030; Q27159055; 3-Pentyl-2-(3-(3-pentyl-2(3H)-benzoxazolylidene)-1-propenyl)benzoxazolium; 3-pentyl-2-[3-(3-pentyl-1,3-benzoxazol-2(3H)-ylidene)prop-1-en-1-yl]-1,3-benzoxazol-3-ium",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C27H33N2O2+",
"molecular_weight": "417.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5486728",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01412"
]
},
{
"compound_ID": "D1261",
"name": "dioc6(3)",
"synonyms": "3,3'-Dihexyl-2,2'-oxacarbocyanine; 54501-79-0; Dioc6(3); 3-Hexyl-2-(3-(3-hexyl-2(3H)-benzoxazolylidene)-1-propenyl)benzoxazolium; SCHEMBL16867337; DTXSID80866308; 3,3'-Dihexaoxycarbocyanine iodide; 3,3'-Dihexyl-2,2'-oxycarbocyanine; NK 2280; NK-2280; Benzoxazolium, 3-hexyl-2-(3-(3-hexyl-2(3H)-benzoxazolylidene)-1-propenyl)-",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C29H37N2O2+",
"molecular_weight": "445.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5702703",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01413"
]
},
{
"compound_ID": "D1262",
"name": "SITS",
"synonyms": "SITS; 27816-59-7; 4-Acetamido-4'-isothiocyanostilbene-2,2'-disulphonic acid; NSC328387; 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid; CHEBI:34383; NSC-328387; Benzenesulfonic acid, 5-(acetylamino)-2-(2-(4-isothiocyanato-2-sulfophenyl)ethenyl)-; 4-Acetamido-4'-isothiocyanostilbene-2,2'-disulfonic acid; 51023-76-8; NSC649691; Benzenesulfonic acid, 5-(acetylamino)-2-[2-(4-isothiocyanato-2-sulfophenyl)ethenyl]-; IADS; NSC 328387; CHEMBL1162149; ZINC3915614; LMPK13090016; NSC-649691; C13702; Q27116033; 4-Isothiocyanato-4'-acetylamino-stilbine-2,2'-disulfonic acid; 5-acetamido-2-[(E)-2-(4-isothiocyanato-2-sulfo-phenyl)vinyl]benzenesulfonic acid",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C17H14N2O7S3",
"molecular_weight": "454.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5282250",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T019"
],
"function": [
"F020103"
],
"references": [
"RC01435",
"RC01436"
]
},
{
"compound_ID": "D1263",
"name": "DIDS",
"synonyms": "dids; 53005-05-3; 4,4'-Diisothiocyanatostilbene-2,2'-disulfonic acid; 4,4'-Diisothiocyanostilbene-2,2'-disulfonic acid; CHEBI:4286; UNII-Q1O6DSW23R; Q1O6DSW23R; CHEMBL1162148; 4,4'-Diisothiocyano-2,2'-Stilbenedisulfonic Acid; 4,4'-Diisothiocyanato-2,2'-stilbenedisulfonic acid; (E)-4,4'-diisothiocyanato-2,2'-stilbenedisulfonic acid; MFCD00065493; DIDS [MI]; SCHEMBL38212; CHEBI:36511; YSCNMFDFYJUPEF-OWOJBTEDSA-N; ZINC6844860; BDBM50044628; LMPK13090003; AKOS015853927; 5-isothiocyanato-2-[(E)-2-(4-isothiocyanato-2-sulfophenyl)ethenyl]benzenesulfonic acid; CC-17158; TR-018767; C11591; A829346; C-22536; Q4036893; BRD-K13872703-304-01-8; Q27891744; 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid; UNII-QHR3Z2PN8M component YSCNMFDFYJUPEF-OWOJBTEDSA-N; 2,2'-ethene-1,2-diylbis(5-isothiocyanatobenzenesulfonic acid); 2,2'-(1,2-Ethenediyl)bis(5-isothiocyanatobenzenesulfonic acid); 2,2'-(E)-ethene-1,2-diylbis(5-isothiocyanatobenzenesulfonic acid); 5,5'-diisothiocyanato-2,2'-(ethene-1,2-diyl)dibenzenesulfonic acid; (E)-6,6'-(ethene-1,2-diyl)bis(3-isothiocyanatobenzenesulfonic acid); 2,2'-[(E)-Ethene-1,2-diyl]bis(5-isothiocyanatobenzenesulfonic acid); 5,5'-diisothiocyanato-2,2'-[(1E)-ethene-1,2-diyl]dibenzenesulfonic acid; 5-isothiocyanato-2-[(E)-2-(4-isothiocyanato-2-sulfo-phenyl)ethenyl]benzenesulfonic acid; 5-isothiocyanato-2-[(E)-2-(4-isothiocyanato-2-sulfo-phenyl)vinyl]benzenesulfonic acid",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C16H10N2O6S4",
"molecular_weight": "454.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5281951",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T019"
],
"function": [
"F020103"
],
"references": [
"RC01437"
]
},
{
"compound_ID": "D1264",
"name": "morin",
"synonyms": "morin; 480-16-0; Aurantica; Calico Yellow; Al-Morin; Toxylon Pomiferum; 2',3,4',5,7-Pentahydroxyflavone; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; Bois d,Arc; Osage Orange; Osage Orange Extract; Bois d'arc; C.I. Natural Yellow 11; C.I. Natural Yellow 8; Osage Orange Crystals; 3,5,7,2',4'-Pentahydroxyflavone; 3,5,7,2',4'-Pentahydroxyflavonol; 2'-Hydroxypelargidenolon 1522; 2',4',3,5,7-Pentahydroxyflavone; C.I. 75660; 2',4',5,7-Tetrahydroxyflavan-3-ol; Zlut prirodni 11; Bois d'arc [French]; UNII-8NFQ3F76WR; Zlut prirodni 11 [Czech]; 4H-1-Benzopyran-4-one, 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-; NSC 19801; C.I. Natural Yellow 11 (VAN); C.I.Natural Yellow 8; NSC19801; EINECS 207-542-9; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; BRN 0327474; 8NFQ3F76WR; Flavone, 2',3,4',5,7-pentahydroxy-; CHEMBL28626; AI3-38057; MLS000069618; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; CHEBI:75092; 3,5 7 2 4-Pentahydroxyflavone; 2',4',5,7-Tetrahydroxyflavonol; 4H-1-Benzopyran-4-one, 2-2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-; NSC-19801; SMR000058259; M-8200; 2-[2,4-bis(oxidanyl)phenyl]-3,5,7-tris(oxidanyl)chromen-4-one; MORIN, REAG; SR-01000000157; CCRIS 8680; Aluminum Ionophore I; Spectrum_001234; regid855692; Spectrum2_000715; Spectrum3_001941; Spectrum4_001924; Spectrum5_000737; Lopac0_000776; SCHEMBL19984; BSPBio_003541; GTPL411; KBioGR_002268; KBioSS_001714; 5-18-05-00492 (Beilstein Handbook Reference); MLS006012034; BIDD:ER0115; DivK1c_000958; SPECTRUM1502259; SPBio_000929; MEGxp0_001864; Morin, p.a., 97.0%; 2',3,5,7-Pentahydroxyflavone; DTXSID1022398; ACon1_000260; BDBM26658; cid_5281670; CTK5B4214; HMS502P20; KBio1_000958; KBio2_001714; KBio2_004282; KBio2_006850; KBio3_002824; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one; 2',4',5,7-Pentahydroxyflavone; 3,7,2',4'-Pentahydroxyflavone; NINDS_000958; YXOLAZRVSSWPPT-UHFFFAOYSA-N; 2',5,7-Tetrahydroxyflavan-3-ol; HMS1921P12; HMS3262K14; Flavone,3,4',5,7-pentahydroxy-; HY-N0621; ZINC3881558; ZX-AT022489; Tox21_500776; BBL036670; CCG-39036; LMPK12112517; MFCD00006826; s9110; SBB008853; STL559049; 2',3,4',5,7-pentahydroxy flavone; 2',3,4',5,7-Pentahydroxy-Flavone; AKOS001582671; LP00776; MCULE-2387347344; SDCCGMLS-0003296.P003; SDCCGSBI-0050754.P003; 2',4',5, 7-Tetrahydroxyflavan-3-ol; IDI1_000958; SMP1_000199; NCGC00015672-01; NCGC00015672-02; NCGC00015672-03; NCGC00015672-04; NCGC00015672-05; NCGC00015672-06; NCGC00015672-07; NCGC00015672-08; NCGC00015672-09; NCGC00015672-10; NCGC00015672-11; NCGC00015672-12; NCGC00015672-13; NCGC00015672-14; NCGC00022214-03; NCGC00022214-04; NCGC00022214-05; NCGC00022214-06; NCGC00022214-07; NCGC00178000-01; NCGC00178000-02; NCGC00261461-01; AK111274; LS-69029; NCI60_001647; SC-44859; AX8140380; DB-051497; 4CH-024478; CS-0009616; EU-0100776; FT-0628989; P0041; ST24039108; ST50308676; X1189; A-9317; C10105; M 4008; Q418224; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromone; 91A9D69E-FAB0-45CD-90E5-DEEFBADE86C1; SR-01000000157-2; SR-01000000157-6; SR-01000000157-7; BRD-K11590034-001-01-0; Aluminum Ionophore I, Selectophore(TM), function tested; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-1-benzopyran-4-one; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one #; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, 9CI; 4H-1-Benzopyran-4-one, 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-,monohydrate; 11128-85-1",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C15H10O7",
"molecular_weight": "302.23",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5281670",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T019"
],
"function": [
"F020103"
],
"references": [
"RC01449"
]
},
{
"compound_ID": "D1265",
"name": "peliomycin",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T019"
],
"function": [
"F020103"
],
"references": [
"RC01463"
]
},
{
"compound_ID": "D1266",
"name": "apoptolidin",
"synonyms": "Apoptolidin; UNII-SAO6WVQ23I; SAO6WVQ23I; FU-40A; CHEMBL4096158; Q27289111",
"trade_name": "",
"abbrev_name": "",
"description": "macrolides (a class of antibiotics); originally produced by Nocardiopsis species; selective cytotoxic agent; polyketide inhibitors of F0F1-ATPase",
"molecular_formula": "C58H96O21",
"molecular_weight": "1129.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "11297771",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T019"
],
"function": [
"F020103",
"F0701"
],
"references": [
"RC01475",
"RC01476",
"RC01480"
]
},
{
"compound_ID": "D1267",
"name": "cytovaricin",
"synonyms": "Cytovaricin; NSC 349622; BRN 4226438; H-230; 79553-45-0; LS-59152",
"trade_name": "",
"abbrev_name": "",
"description": "polyketide inhibitors of F0F1-ATPase,",
"molecular_formula": "C47H80O16",
"molecular_weight": "901.1",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "6436235",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T019"
],
"function": [
"F020103",
"F0701"
],
"references": [
"RC01477",
"RC01478",
"RC01481"
]
},
{
"compound_ID": "D1268",
"name": "1h-benzimidazol-5-amine-2-4-aminophenyl",
"synonyms": "7621-86-5; 2-(4-Aminophenyl)-1H-benzo[d]imidazol-5-amine; 2-(4-Aminophenyl)-1H-benzimidazol-5-amine; 1H-Benzimidazol-5-amine, 2-(4-aminophenyl)-; 2-(4-Aminophenyl)-5-aminobenzimidazole; 2-(4-Aminophenyl)-1H-benzimidazol-2-amine; Benzimidazole, 5-amino-2-(p-aminophenyl)-; EINECS 231-538-6; NSC 408148; 5-amino-2-(4-aminophenyl)benzimidazole; MLS000764524; 1H-Benzimidazol-6-amine, 2-(4-aminophenyl)-; XAFOTXWPFVZQAZ-UHFFFAOYSA-N; SMR000290129; 2-(4-aminophenyl)-1H-1,3-benzodiazol-5-amine; 2-(4-aminophenyl)-1H-1,3-benzodiazol-6-amine; 2-(4-aminophenyl)benzimidazole-5-ylamine; NSC408148; 5-amino-2-(p-aminophenyl)benzimidazole; 2-(4-aminophenyl)-3H-benzimidazol-5-amine; Cambridge id 5137121; 2-(4-Amino-phenyl)-1H-benzoimidazol-5-ylamine; Oprea1_073783; Oprea1_196638; Oprea1_357955; CBDivE_010161; cid_24260; SCHEMBL159873; CHEMBL1489074; DTXSID0064755; SCHEMBL15144987; BDBM53882; CTK5E2602; HMS2667O03; ZINC297475; ACT05540; ANW-45201; CCG-15105; SBB000645; STK266257; AKOS000115437; AKOS000601336; MCULE-4375315815; NE11002; NSC-408148; 2-(4-aminophenyl)-6-aminobenzimidazole; 2-(p-aminophenyl)-5-aminobenzimidazole; NCGC00245118-01; 2-(4-aminophenyl)-6-amino benzimidazole; 2-(4-aminophenyl)-6-amino-benzimidazole; AS-66542; BP-13089; LS-32540; ST001543; 2-(4'-aminophenyl) 5-amino benzimidazole; 4-(5-Amino-1H-benzimidazole-2-yl)aniline; Benzimidazol-5-amine, 2-(4-aminophenyl)-; DB-003864; ST2416096; TC-133946; 2-(4'-amino-phenyl)-5-amino-benzimidazole; CS-0095841; FT-0699611; 1H-Benzimidazol-6-amine,2-(4-aminophenyl)-; EN300-02411; [4-(6-amino-1H-benzimidazol-2-yl)phenyl]amine; 621A865; SR-01000389407; 2- pound 4-AMINOPHENIL)-5-AMINOBENZIMIDAZOLE; SR-01000389407-1; Z56862335; 6-Amino-2-(4-imino-2,5-cyclohexadiene-1-ylidene)-2,3-dihydro-1H-benzimidazole",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C13H12N4",
"molecular_weight": "224.26",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "24260",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F02110103"
],
"references": [
"RC01483"
]
},
{
"compound_ID": "D1269",
"name": "phenalamid a2",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01358"
]
},
{
"compound_ID": "D1270",
"name": "Thiangazole",
"synonyms": "Thiangazole; (-)-Thiangazole; 138667-71-7; Thiangazole A; 4-Oxazolecarboxamide,2-(4,4',4'',5,5',5''-hexahydro-4,4',4''-trimethyl-2''-(2-phenylethenyl)(2,4':2',4''-terthiazol)-4-yl)-N,5-dimethyl-, (4R-(2(2'(2''(E),4''S*),4'S*),4R*))-; 4-Oxazolecarboxamide,2-[4,4',4'',5,5',5''-hexahydro-4,4',4''-trimethyl-2''-(2-phenylethenyl)[2,4':2',4''-terthiazol]-4-yl]-N,5-dimethyl-, [4R-[2[2'[2''(E),4''S*],4'S*],4R*]]-; SCHEMBL13342866; N,5-dimethyl-2-[(4R)-4-methyl-2-[(4S)-4-methyl-2-[(4S)-4-methyl-2-[(E)-styryl]-5H-thiazol-4-yl]-5H-thiazol-4-yl]-5H-thiazol-4-yl]oxazole-4-carboxamide",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C26H29N5O2S3",
"molecular_weight": "539.7",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "6451119",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01356"
]
},
{
"compound_ID": "D1271",
"name": "myxalamid pi",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [
"T001"
],
"function": [
"F020103"
],
"references": [
"RC01357"
]
},
{
"compound_ID": "D1272",
"name": "beta-methoxyacrylate stilbene",
"synonyms": "",
"trade_name": "",
"abbrev_name": "MOAS",
"description": "contain a beta-methoxyacrylate (MOA) group; referred to as the MOA inhibitors; they presumably block the ET from quinol to the ISP, accompanying a red-shift in the alpha and beta-bands of the reduced heme bL spectrum.; class Ia inhibitors of Complex III",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [],
"references": []
},
{
"compound_ID": "D1273",
"name": "dicarbopolyborate",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "Polyborate anions",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [],
"references": []
},
{
"compound_ID": "D1274",
"name": "ranolazine",
"synonyms": "partial fatty-acid-oxidation inhibitor (pFOX inhibitor); antianginal drug; metabolic modifier; assumed to be partial FAO inhibitors that targeted 3-ketoacyl-CoA thiolase (3-KAT), a component of the trifunctional protein (hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase/3-KAT)",
"trade_name": "Ranexa",
"abbrev_name": "",
"description": "partial fatty-acid-oxidation inhibitor (pFOX inhibitor); antianginal drug; metabolic modifier; assumed to be partial FAO inhibitors that targeted 3-ketoacyl-CoA thiolase (3-KAT), a component of the trifunctional protein (TFP) (hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase/3-KAT)",
"molecular_formula": "C24H33N3O4",
"molecular_weight": "427.5",
"state": "solid",
"clearance": "The clearance rate of ranolazine is dose-dependent and the presence of mild-to-moderate renal impairment can increase serum concentration by 40-50%.[A174946] The reported clearance rate of orally administered ranolazine is of 45 L/h when administered a concentration of 500 mg twice daily.[A38645]",
"volume_of_distribution": "The mean apparent volume of distribution of ranolazine is reported to be of 53.2 L[L5473] and the mean steady-state volume of distribution is of about 180L.[F3616]",
"route_of_elimination": "From the administered dose, about 75% is excreted renally.[A174898] From this eliminated dose, only about 5% is represented by the unchanged drug.[A174946]",
"protein_binding": "In the human body, about 62% of the administered dose of ranolazine is bound to proteins.[A174946] From the studies related to binding in plasma proteins, ranolazine seems to have a higher affinity for alpha-1 acid glycoprotein.[F3616]",
"half_life": "Due to the short half-life of the immediate release formulation of ranolazine (1.4-1.9 hours), it was required the generation of an extended-release formulation which presented an approximate steady-state half-life of 7-9 hours.[A174898]",
"absorption": "The time to reach peak serum concentration is very variable but it has been suggested to be of 2-6 hours and to reach steady-state within 3 days.[A174898] The absorption of ranolazine is not modified by food consumption.[A174940] The bioavailability of ranolazine is reported to be of about 73% counting both the unchanged form and the metabolites. After multiple administration of a dose of 500 mg, the reported Cmax and AUC were 1770 ng/ml and 13700 ng.h/ml respectively.[L5473]",
"cid": "56959",
"classification": "C",
"indications": "",
"side_effects": "",
"atc_codes": "C01EB18",
"group": "Drug",
"drug_type": "",
"target": [
"T086001"
],
"function": [
"F020401",
"F020601",
"F02060101"
],
"references": [
"RC00876",
"RC00877",
"RC03762",
"RC03772"
]
},
{
"compound_ID": "D1275",
"name": "glyceraldehyde 3-phosphate",
"synonyms": "DL-Glyceraldehyde 3-phosphate; 3-phosphoglyceraldehyde; glyceraldehyde-3-phosphate; GLYCERALDEHYDE 3-PHOSPHATE; 591-59-3; 142-10-9; 2-hydroxy-3-oxopropyl dihydrogen phosphate; Glycerinaldehyd-3-phosphat; glyceraldehyde-P; Glyceraldehyde 3 Phosphate; Propanal, 2-hydroxy-3-(phosphonooxy)-; glyceraldehyde-3-P; D-glyceraldehyde-3-P; glyceraldehyde-phosphate; Glyceraldehyde-3P; 2-hydroxy-3-(phosphonooxy)propanal; EINECS 209-721-7; DL-GLYCERALDEHYDE-3-PHOSPHATE; D-glyceraldehyde-3P; gliceraldehido-3-fosfato; Glyzerinaldehyd-3-phosphat; gap; SCHEMBL34088; CHEBI:17138; CTK0H5543; DTXSID40861814; 2-hydroxy-3-(phosphonooxy)-Propanal; FCH838708; AKOS006274614; glyceraldehyde 3-(dihydrogen phosphate); HY-113054; CS-0059450; FT-0695022; NS00043632; NS00069415; C00661; 48375-EP2305825A1; 48375-EP2311494A1; C-44401; Q794810; CAFD4B5D-3480-4F4B-BE65-FF404EDB74FC; DL-Glyceraldehyde 3-phosphate - 45-55 mg/mL aqueous solution; DL-Glyceraldehyde 3-phosphate solution, 45-55 mg/mL in H2O",
"trade_name": "",
"abbrev_name": "G3P, GA3P, GADP, GAP, TP, GALP or PGAL",
"description": "glycolytic intermediate",
"molecular_formula": "C3H7O6P",
"molecular_weight": "170.06",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "729",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F0108",
"F050401"
],
"references": [
"RC03478",
"RC03480"
]
},
{
"compound_ID": "D1276",
"name": "dihydroxyacetone phosphate",
"synonyms": "DIHYDROXYACETONE PHOSPHATE; DHAP; Glycerone phosphate; 1-Hydroxy-3-(phosphonooxy)acetone; 57-04-5; 2-Propanone, 1-hydroxy-3-(phosphonooxy)-; 1-hydroxy-3-(phosphonooxy)-2-propanone; Dihydroxyacetone monophosphate; 3-hydroxy-2-oxopropyl phosphate; 1,3-Dihydroxyacetone 1-phosphate; dihydroxyacetone 3-phosphate; UNII-T7KF2T6W95; 1,3-Dihydroxy-2-propanone phosphate; Dihydroxy-Acetone-P; glycerone monophosphate; 1,3-DIHYDROXYACETONEPHOSPHATE; 3-hydroxy-2-oxopropyl dihydrogen phosphate; T7KF2T6W95; CHEBI:16108; (3-hydroxy-2-oxopropoxy)phosphonic acid; dihydroxyacetone-P; di-OH-acetone-P; 1,3-Dihydroxy-2-propanone monodihydrogen phosphate; 1ado; glycerone-phosphate; EINECS 200-308-7; dihydroxyacetone-phosphate; dihydroxy-acetone-phosphate; (3-hydroxy-2-oxopropyl) dihydrogen phosphate; SCHEMBL43277; CHEMBL1161998; DTXSID6058768; CTK8D6962; ZINC24492326; DB04326; 2-Propanone, 1-hydroxy-3-(phosphonooxy); HY-113131; CS-0060244; NS00033636; C00111; 2-Propanone, 1,3-dihydroxy-, phosphate (6CI); Q416915; 1,3-dihydroxy-2-Propanone mono(dihydrogen phosphate); Phosphoric acid ester with 1,3-dihydroxy-2-propanone; Dihydroxyacetone phosphate lithium salt, >=95.0% (TLC); C3A185EA-003E-4498-872D-9933185C777F; Phosphoric acid, ester with 1,3-dihydroxy-2-propanone (6CI); 2-Propanone, 1,3-dihydroxy-, mono(dihydrogen phosphate) (8CI)",
"trade_name": "",
"abbrev_name": "DHAP",
"description": "glycolytic intermediate; product of mGPDH; phosphate ester of dihydroxyacetone",
"molecular_formula": "C3H7O6P",
"molecular_weight": "170.06",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "668",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [
"T181"
],
"function": [
"F0108",
"F050401"
],
"references": [
"RC03479",
"RC03481"
]
},
{
"compound_ID": "D1277",
"name": "rosuvastatin",
"synonyms": "Rosuvastatin; 287714-41-4; Rosuvastatin calcium; ZD4522; UNII-413KH5ZJ73; CHEMBL1496; CHEBI:38545; 413KH5ZJ73; ZD-4522; (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid; Creston (TN); Rosuvastatin (INN); (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; Rosuvastatin [INN:BAN]; C22H28FN3O6S; HSDB 7317; Spectrum5_001695; Rosuvastatin;ROSUVASTATIN; SCHEMBL2520; BSPBio_003429; SCHEMBL154400; SPECTRUM1505213; GTPL2954; DTXSID8048492; BDBM18372; CHEBI:93454; HMS1922N09; ZINC1535101; CCG-40119; HY-17504A; AKOS000280777; AM84890; CS-2112; DB01098; NCGC00178070-01; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); AS-12247; SBI-0206727.P001; LS-187345; S5072; A11122; A24862; D08492; 28050-EP2269990A1; 28050-EP2272841A1; 28050-EP2272842A1; 28050-EP2280006A1; 28050-EP2281813A1; 28050-EP2284158A1; 28050-EP2287165A2; 28050-EP2287166A2; 28050-EP2292620A2; 28050-EP2295406A1; 28050-EP2298731A1; 28050-EP2298742A1; 28050-EP2298745A1; 28050-EP2298772A1; 28050-EP2298776A1; 28050-EP2298779A1; 28050-EP2301923A1; 28050-EP2301931A1; 28050-EP2301936A1; 28050-EP2308839A1; 28050-EP2314588A1; Q415159; BRD-K82941592-001-01-3; BRD-K82941592-238-02-9; (3R,5S)-7-[4-(4-fluorophenyl)-2-(methyl-methylsulfonylamino)-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-trans-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[4-(4-Fluorophenyl)-2-[(methanesulfonyl)(methyl)amino]-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3r,5s,6e)-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid; (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6enoic acid; (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid; 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-; 7-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl-methylsulfonyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoic acid;Rosuvastatin;Rosuvastatin Acid; E-(7-{2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-yl}-(3R,5S)-3,5-dihydroxy-hept-6-enoic acid]; E-7-[2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid; FBI",
"trade_name": "Crestor",
"abbrev_name": "",
"description": "statin; lipid-lowering drug; inhibiting HMG-CoA reductase",
"molecular_formula": "C22H28FN3O6S",
"molecular_weight": "481.5",
"state": "solid",
"clearance": "",
"volume_of_distribution": "* 134 L [steady-state]",
"route_of_elimination": "Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route.",
"protein_binding": "88% bound to plasma proteins (mostly albumin). Binding is reversible and independent of plasma concentrations.",
"half_life": "19 hours",
"absorption": "Bioavailability is approximately 20%. Peak plasma concentrations were reached 3 to 5 hours following oral dosing. Both Cmax and AUC increased in approximate proportion to CRESTOR dose. Food has no effect on the AUC of rosuvastatin.",
"cid": "446157",
"classification": "G; A; C",
"indications": "",
"side_effects": "",
"atc_codes": "C10BX09; C10BX05; C10BA06; C10AA07; G01AE10; C10BX14; A10BH52; C10BX07; C10BX10; C10BX13",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [],
"references": []
},
{
"compound_ID": "D1278",
"name": "ionomycin",
"synonyms": "ionomycin; 56092-81-0; Ionomycin free acid; UNII-54V905V6AT; CHEBI:63954; Ionomycin, Free Acid, Streptomyces conglobatus; 54V905V6AT; C41H72O9; (4R,6S,8S,10Z,12R,14R,16E,18R,19R,20S,21S)-11,19,21-trihydroxy-22-{(2S,2'R,5S,5'S)-5'-[(1R)-1-hydroxyethyl]-2,5'-dimethyloctahydro-2,2'-bifuran-5-yl}-4,6,8,12,14,18,20-heptamethyl-9-oxodocosa-10,16-dienoic acid; (4R,6S,8S,10Z,12R,14R,16E,18R,19R,20S,21S)-11,19,21-Trihydroxy-4,6,8,12,14,18,20-heptamethyl-22-[(2S,2'R,5S,5'S)-octahydro-5'-[(1R)-1-hydroxyethyl]-2,5'-dimethyl[2,2'-bifuran]-5-yl]-9-oxo-10,16-docosadienoic acid; CHEMBL501617; DTXSID2040521; SCHEMBL17265597; Ionomycin, Free Acid, Streptomyces conglobatus in Solution; HMS3403I13; HSCI1_000207; MFCD06798385; AKOS024456942; ZINC169289396; AS-56129; HY-13434; CS-0006887; X6869; Ionomycin from Streptomyces conglobatus, >=98% (HPLC)",
"trade_name": "",
"abbrev_name": "",
"description": "Ca2+ ionophore; antibiotic ; ionophore that binds calcium ions in a ratio 1:1;",
"molecular_formula": "C41H72O9",
"molecular_weight": "709",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "6912226",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F010605",
"F02010202"
],
"references": [
"RC03493",
"RC03495",
"RC03496"
]
},
{
"compound_ID": "D1279",
"name": "A23187",
"synonyms": "Calcimycin; Ionophore A23187; Antibiotic A23187; C29H37N3O6; 52665-69-7; A 23187; A23187; CHEBI:3305; Calcium ionophore A23187; A-23187; EINECS 258-084-1; A23187, free acid; 4-Benzoxazolecarboxylic acid, 5-(methylamino)-2-((3,9,11-trimethyl-8-(1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl)-1,7-dioxaspiro(5.5)undec-2-yl)methyl)-, (6S-(6alpha(2S*,3S*),8beta(R*),9beta,11alpha))-; Spectrum_001976; UPCMLD-DP093; CBiol_001742; BSPBio_001576; KBioGR_000296; KBioSS_000296; KBioSS_002542; DivK1c_000618; SCHEMBL258988; CHEMBL1434752; DTXSID1040405; UPCMLD-DP093:001; UPCMLD-DP093:002; UPCMLD-DP093:003; HMS501O20; KBio1_000618; KBio2_000296; KBio2_002533; KBio2_002864; KBio2_005101; KBio2_005432; KBio2_007669; KBio3_000591; KBio3_000592; NINDS_000618; Bio1_000028; Bio1_000517; Bio1_001006; Bio2_000296; Bio2_000776; HMS1361O18; HMS1791O18; HMS1989O18; HMS3402O18; Calcium ionophore;4-Benzoxazolecarboxylic acid, 5-(methylamino)-2-[[3,9,11-trimethyl-8-[1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl]-1,7-dioxaspiro[5.5]undec-2-yl]methyl]-, [6S-[6a(2S*,3S*),8ss(R*),9ss,11a]]-; CCG-208023; CCG-208154; IDI1_000618; IDI1_034046; SMP2_000029; NCGC00161647-01; LS-42155; C11309; BRD-A19134330-001-03-8; Q27106018; 4-Benzoxazolecarboxylic acid, 5-(methylamino)-2-((3,9,11-trimethyl-8-(1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl)-1,7-dioxaspiro(5.5)undec-2-yl)methyl), (6S-(6-alpha(2S*,3S*),8-beta(R*),9-beta,11-alpha))-; 5-(methylamino)-2-({(2S,3S,8S,9R,11R)-3,9,11-trimethyl-8-[1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undec-2-yl}methyl)-1,3-benzoxazole-4-carboxylic acid; 5-(methylamino)-2-[[(2S,3R,5R,8S,9S)-3,5,9-trimethyl-2-[1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid; 5-(methylamino)-2-[[(3S,4S,7R,9R,10S)-3,7,9-trimethyl-10-[1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl]-5,11-dioxaspiro[5.5]undecan-4-yl]methyl]-1,3-benzoxazole-4-carboxylic acid; 5-(Methylamino)-2-[[2R,3R,6S,8S,9R,11R)-3,9,11-trimethyl-8-[(1S)-1-methyl-2-oxo-2-(1H-pyr rol-2-yl)-ethyl]-1,7-dioxaspiro[5.5]undec-2-yl]methyl]-4-benzoxazolecarboxylic acid; 6S-[6.alpha.(2S*,3S*),8.beta.(R*),9.beta.11. alpha.]-5-(Methylamino)-2-[[3,9,11-trimethyl-8- [1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl]-1,7- dioxaspiro[5,5]undec-2-yl]methyl-4- benzoxazolecarboxylic aci",
"trade_name": "",
"abbrev_name": "",
"description": "Ca2+ ionophore",
"molecular_formula": "C29H37N3O6",
"molecular_weight": "523.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "11957499",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F010605"
],
"references": [
"RC03492",
"RC03497"
]
},
{
"compound_ID": "D1280",
"name": "X-537A",
"synonyms": "lasalocid; Lasalocid A; Lasalocide; 25999-31-9; Lasalocidum; Lasalocido; Ionophore X 537A; Antibiotic X 537A; Lasalocide A; UNII-W7V2ZZ2FWB; Lasalocide [INN-French]; Lasalocidum [INN-Latin]; Lasalocido [INN-Spanish]; X 537A; X-537A; EINECS 247-401-9; Ro 2-2985; W7V2ZZ2FWB; NSC 243048; 6-(7(R)-(5(S)-Ethyl-5-(5(R)-ethyltetrahydro-5-hydroxy-6(S)-methyl-2H-pyran-2(R)-yl)tetrahydro-3(S)-methyl-2(S)-furyl)-4(S)-hydroxy-3(R),5(S)-dimethyl-6-oxononyl)-2,3-cresotic acid; 6-(7-(5-Ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furanyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-2-hydroxy-3-methylbenzoic acid (2R-(2alpha(2S*(3R*,4S*,5S*,7R*),3S*,5S*),5alpha,6beta))-; Benzoic acid, 6-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furanyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-2-hydroxy-3-methyl-, (2R-(2alpha(2S*(3R*,4S*,5S*,7R*),3S*,5S*),5alpha,6beta))-; (1S,9S)-1,5:6,9-Dianhydro-9-[(3R,5S,6S,7R)-9-(2-carboxy-3-hydroxy-4-methylphenyl)-6-hydroxy-5,7-dimethyl-4-oxononan-3-yl]-3,4,7,8-tetradeoxy-6-ethyl-2-C-ethyl-1,8-dimethyl-D-galacto-nonitol; (2R-(2alpha(2S*(3R*,4S*,5S*,7R*)3S*,5S*),5alpha,6beta))-6-(7-(5-Ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-3-methylsalicylic acid; 2,3-Cresotic acid, 6-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-, (-)-; 6-(7(R)-(5(S)-Ethyl-5-(R)-ethyltetrahydro-5-hydroxy-6(S)-methyl-2H-pyran-2(R)-yl)tetrahydro-3(S)-methyl-2(S)-furyl)-4(S)-hydroxy-3(R),5(S)-dimethyl-6-oxononyl)-2,3-cresotic acid; 6-[(3R,4S,5S,7R)-7-{(2S,3S,5S)-5-ethyl-5-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]-3-methyltetrahydrofuran-2-yl}-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methylbenzoic acid; Benzoic acid, 6-((3R,4S,5S,7R)-7-((2S,3S,5S)-5-ethyl-5-((2R,5R,6S)-5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furanyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-2-hydroxy-3-methyl-; Benzoic acid, 6-(7(R)-(5(S)-Ethyl-5-(5(R)-ethyltetrahydro-5-hydroxy-6(S)-methyl-2H-pyran-2(R)-yl)tetrahydro-3(S)-methyl-2(S)-furanyl)-4(S)-hydroxy-3(R),5(S)-dimethyl-6-oxononyl)-2-hydroxy-3-methyl-; Benzoic acid,6-[7-[5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furanyl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methyl-, [2R-[2a[2S*(3R*,4S*,5S*,7R*),3S*,5S*],5a,6b]]-; NSC243046; 25999-20-6; Lasalocid [USAN:BAN:INN]; Lasalocid [USAN:INN:BAN]; Lasalocid (USAN/INN); Prestwick0_000828; Prestwick1_000828; Prestwick2_000828; Prestwick3_000828; Lasalocid (X 537 A); BSPBio_000755; SCHEMBL259623; SPBio_002676; BPBio1_000831; CHEMBL145347; MEGxm0_000441; DTXSID9048485; ACon0_000529; ACon1_002071; CHEBI:92181; CTK4H7956; Benzoic acid, 6-[7-[5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furanyl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methyl-, monosodium salt, [2R-[2?[2S*(3R*,4S*,5S*,7R*),3S*,5S*],5?,6?]]-; HY-B1071; ZINC4216707; LMPK09000002; Ro-22985; CS-4627; DB11423; MCULE-5612044177; NCGC00179860-02; LS-55461; D04671; J-016218; Q3827314; Antibiotic X-537A;Lasalocid-A;X-537A;Ionophore X-537A; (1S,9S)-1,5:6,9-Dianhydro-9-[(3R,5S,6S,7R)-9-(2-carboxy-3-hydroxy-4-methylphenyl)-6-hydroxy-5,7-dimethyl-4-oxo-3-nonanyl]-3,4,7,8-tetradeoxy-6-ethyl-2-C-ethyl-1,8-dimethyl-D-galacto-nonitol; 37259-88-4; 6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-ETHYL-5-[(2R,5R,6S)-5-ETHYL-5-HYDROXY-6-METHYL-OXAN-2-YL]-3-METHYL-OXOLAN-2-YL]-4-HYDROXY-3,5-DIMETHYL-6-OXO-NONYL]-2-HYDROXY-3-METHYL-BENZOIC ACID; 6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-ethyl-5-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyl-tetrahydropyran-2-yl]-3-methyl-tetrahydrofuran-2-yl]-4-hydroxy-3,5-dimethyl-6-oxo-nonyl]-2-hydroxy-3-methyl-benzoic acid; 6-{7-[(5S)-5-((6S,5R)-5-Ethyl-5-hydroxy-6-methylperhydro-2H-pyran-2-yl)-5-ethyl-3-methyloxolan-2-yl](4S,5S,3R,7R)-4-hydroxy-3,5-dimethyl-6-oxononyl}-2-hydroxy-3-methylbenzoic acid; NCGC00179860-02!6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-ethyl-5-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-3-methyloxolan-2-yl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methylbenzoic acid",
"trade_name": "Lasalocid",
"abbrev_name": "",
"description": "Ca2+ ionophore; antibiotic;",
"molecular_formula": "C34H54O8",
"molecular_weight": "590.8",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5360807",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F010606"
],
"references": [
"RC03494"
]
},
{
"compound_ID": "D1281",
"name": "AJ-9677",
"synonyms": "Rafabegron; 244081-42-3; UNII-LN3E1Q0SU2; AJ-9677; LN3E1Q0SU2; CHEMBL279260; Rafabegron [INN]; 3-CP-2-HE-API-AA; TAK 677; TAK-677; (3-((2R)-2-((2R)-2-(3-Chlorophenyl)-2-hydroxyethylamino)propyl)-1H-indol-7-yloxy)acetic acid; (3-{(2R)-2-((2R)-2-(3-Chlorophenyl)-2-hydroxyethylamino)propyl}-1H-indol-7-yloxy)acetic acid; AD 9677; AD-9677; AJ 9677; SCHEMBL678589; CTK4F3608; DTXSID80179162; 2-((3-((R)-2-(((R)-2-(3-Chlorophenyl)-2-hydroxyethyl)amino)propyl)-1H-indol-7-yl)oxy)acetic acid; ZINC3952725; BDBM50126069; 2-[[3-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yl]oxy]acetic acid; LS-190831; Q27283076; (3-{2-[(R)-2-((R)-3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl}-1H-indol-7-yloxy)-acetic acid; Acetic acid,2-[[3-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yl]oxy]-",
"trade_name": "",
"abbrev_name": "",
"description": "selective beta3-adrenoceptor agonist;",
"molecular_formula": "C21H23ClN2O4",
"molecular_weight": "402.9",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5493324",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T221"
],
"function": [],
"references": [
"RC03498",
"RC03499"
]
},
{
"compound_ID": "D1282",
"name": "dianemycin",
"synonyms": "Dianemycin; NSC 138320; BRN 1676784; MLS002702009; 35865-33-9; NSC138320; CHEMBL1723966; NSC-138320; LS-59584; SMR001565584; (6E)-8-(9-Hydroxy-2-{2-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethylperhydro-2H-pyran-2-yl]-9-(5-methoxy-6-methylperhydro-2H-pyran-2-yloxy)-4,10-dimethyl-1,6-dioxaspiro[4.5]dec-7-yl}-2,8-dimethyl-1,6-dioxaspiro[4.5]dec-7-yl)-2,4,6-trimethyl-5-oxonon-6-enoic acid; (E)-8-[7-hydroxy-2-[2-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-9-(5-methoxy-6-methyloxan-2-yl)oxy-4,10-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-2,4,6-trimethyl-5-oxonon-6-enoic acid; (E)-8-[7-hydroxy-3-[3-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-tetrahydropyran-2-yl]-7-(5-methoxy-6-methyl-tetrahydropyran-2-yl)oxy-1,6-dimethyl-4,10-dioxaspiro[4.5]decan-9-yl]-3,8-dimethyl-4,10-dioxaspiro[4.5]decan-9-yl]-2,4,6-trimethyl-5-oxo-non-6-enoic acid",
"trade_name": "",
"abbrev_name": "",
"description": "polyether antibiotic; sodium ionophore",
"molecular_formula": "C47H78O14",
"molecular_weight": "867.1",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5475287",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F010604"
],
"references": [
"RC03491"
]
},
{
"compound_ID": "D1283",
"name": "monensin",
"synonyms": "monensin; Monensic acid; monensin A; Monensina; Monensinum; 17090-79-8; UNII-906O0YJ6ZP; Elancoban; Monelan; 906O0YJ6ZP; CHEBI:27617; A 3823A; Rumensin; Coban (as sodium salt); Monensinum [INN-Latin]; Monensina [INN-Spanish]; Rumensin (as sodium salt); Lilly 673140; HSDB 7031; ATCC 15413; EINECS 241-154-0; Rumensin 90; (2S,3R,4S)-4-[(2S,5R,7S,8R,9S)-2-{(2S,2'R,3'S,5R,5'R)-2-ethyl-5'-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyltetrahydro-2H-pyran-2-yl]-3'-methyloctahydro-2,2'-bifuran-5-yl}-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]dec-7-yl]-3-methoxy-2-methylpentanoic acid; NSC343257; Monensine; Monensin [USAN:USP:INN:BAN]; Monensin (INN); Stereoisomer of 2-(2-ethyloctahydro-3'-methyl-5'-(tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl)(2,2'-bifuran-5-yl))-9-hydroxy-beta-methoxy-alpha,gamma,2,8-tetramethyl-1,6-dioxaspiro(4.5)decan-7-butanoic acid; Prestwick3_000748; SCHEMBL55367; BSPBio_000736; Elancoban [veterinary] (TN); BPBio1_000810; CHEMBL256105; DTXSID4048561; 1,6-Dioxaspiro(4.5)decane-7-butyric acid, 2-(5-ethyltetrahydro-5-(tetrahydro-3-methyl-5-(tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl)-2-furyl)-2-furyl)-9-hydroxy-beta-methoxy-alpha,gamma,2,8-tetramethyl-; 1392-52-5; 2-[5-Ethyltetrahydro-5-[tetrahydro-3-methyl-5-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl]-2-furyl]-2-furyl]-9-hydroxy-.beta.-methoxy-.alpha.,.gamma.,2,8-tetramethyl-1,6-dioxaspiro[4.5]decane-7-butyric acid; ZINC8143466; AKOS015964837; DB11430; E714; C06693; D08228; monensin;Monensin sodium;Monensin, monosodium salt; J-010665; Q3493048; SR-05000013702-2; BRD-K55375480-236-03-0; (2S,3R,4S)-4-[(2S,5R,7S,8R,9S)-2-{(2S,2'R,3'S,5R,5'R)-2-Ethyl-5'-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3'-methyl[2,2'-bioxolan]-5-yl}-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-3-methoxy-2-methylpentanoic acid; (2S,3R,4S)-4-[(2S,5R,7S,8R,9S)-2-{(2S,2'R,3'S,5R,5'R)-2-Ethyl-5'-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyltetrahydro-2H-pyran-2-yl]-3'-methyloctahydro-2,2'-bifuran-5-yl}-9-hydroxy-2,8-di; (2S,3R,4S)-4-[(3S,5R,7S,8R,9S)-3-[(2R,5S)-5-ethyl-5-[(2R,3S,5R)-5-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-tetrahydropyran-2-yl]-3-methyl-tetrahydrofuran-2-yl]tetrahydrofuran-2-yl]-7-hydroxy-3,8-dimethyl-4,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methyl-pentanoic acid",
"trade_name": "",
"abbrev_name": "",
"description": "polyether antibiotic isolated from Streptomyces cinnamonensis; sodium ionophore",
"molecular_formula": "C36H62O11",
"molecular_weight": "670.9",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "441145",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F010604"
],
"references": [
"RC03490"
]
},
{
"compound_ID": "D1284",
"name": "serotonin",
"synonyms": "serotonin; 5-HYDROXYTRYPTAMINE; 3-(2-Aminoethyl)-1H-indol-5-ol; 50-67-9; Enteramine; 5-HT; Thrombocytin; Thrombotonin; Antemovis; Serotonine; Ds substance; Hippophain; Antemoqua; 1H-Indol-5-ol, 3-(2-aminoethyl)-; Substance DS; Substanz DS; 3-(2-Aminoethyl)indol-5-ol; 5-Hta; Tryptamine, 5-hydroxy-; Enteramin; UNII-333DO1RDJY; Indol-5-ol, 3-(2-aminoethyl)-; 3-(beta-Aminoethyl)-5-hydroxyindole; 5-Hydroxy-3-(beta-aminoethyl)indole; EINECS 200-058-9; 3-(2-Amino-ethyl)-1H-indol-5-ol; BRN 0143524; 333DO1RDJY; CHEBI:28790; 1H-Indol-5-ol,3-(2-aminoethyl)-; Hippophaine; H-8000; [3H]-5-HT; erotonin; 5-hydroxytryptamin; 5-Hydroxytriptamine; 5-Hydroxyltryptamine; 5-hydroxy-tryptamine; 5-hydroxyl tryptamine; GTPL5; CHEMBL39; Prestwick0_000481; Prestwick1_000481; Prestwick2_000481; Prestwick3_000481; Lopac-H-9523; Biomol-NT_000083; bmse000757; SCHEMBL1495; Lopac0_000607; Oprea1_712368; BSPBio_000341; BSPBio_001112; KBioGR_000452; KBioGR_002472; KBioSS_000452; KBioSS_002479; 5-22-12-00016 (Beilstein Handbook Reference); Serotonin, analytical standard; SPBio_002262; 5-Hydroxytryptamine, free base; BPBio1_000377; BPBio1_001079; DTXSID8075330; BCBcMAP01_000198; BDBM10755; CTK4J2994; KBio2_000452; KBio2_002472; KBio2_003020; KBio2_005040; KBio2_005588; KBio2_007608; KBio3_000843; KBio3_000844; KBio3_002950; ZINC57058; cMAP_000059; 3-(b-Aminoethyl)-5-hydroxyindole; 5-Hydroxy-3-(b-aminoethyl)indole; Bio1_000450; Bio1_000939; Bio1_001428; Bio2_000396; Bio2_000876; HMS1362H13; HMS1792H13; HMS1990H13; HMS3403H13; 3-(2-Aminoethyl)-1H-indol-5-o; ALBB-006183; 6996AB; FCH832159; PDSP1_001512; PDSP2_001496; STK503758; AKOS001484724; 3-(2-Aminoethyl)-1H-indol-5-ol #; API0006544; CCG-204696; DB08839; MCULE-8788459983; SDCCGSBI-0050589.P002; 3-(.beta.-Aminoethyl)-5-hydroxyindole; 5-Hydroxy-3-(.beta.-aminoethyl)indole; IDI1_002151; SMP1_000272; 5-hydroxy tryptamine creatinine disulfate; NCGC00015525-01; NCGC00015525-02; NCGC00015525-03; NCGC00015525-04; NCGC00015525-05; NCGC00015525-06; NCGC00015525-07; NCGC00015525-08; NCGC00015525-09; NCGC00142449-01; NCGC00142449-02; NCGC00142449-03; NCGC00142449-04; NCGC00142449-05; CAS-153-98-0; CC-21879; LS-83647; AX8011985; DB-051820; FT-0631212; NS00007188; 14C-5-hydroxy tryptamine creatinine disulfate; C00780; K-9367; C-06146; L000078; Q167934; 6F7FD5B4-A558-45F0-A20A-2D068A3EFE6A; 2-imino-1-methylimidazolidin-4-one; 3-(2-aminoethyl)-1H-indol-5-ol; bis(sulfuric acid); 1094000-36-8; Serotonin;3-(2-aminoethyl)indol-5-ol;3-(2-aminoethyl)indol-5-ol--2-imino-1-methylimidazolidin-4-one sulphate (1:1)",
"trade_name": "",
"abbrev_name": "5-HT",
"description": "monoamine neurotransmitter",
"molecular_formula": "C10H12N2O",
"molecular_weight": "176.21",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5202",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0401"
],
"references": [
"RC03582"
]
},
{
"compound_ID": "D1285",
"name": "dopamine",
"synonyms": "dopamine; 4-(2-Aminoethyl)benzene-1,2-diol; 51-61-6; Dopamin; 3-Hydroxytyramine; Hydroxytyramin; Oxytyramine; 3,4-dihydroxyphenethylamine; intropin; Dophamine; 2-(3,4-dihydroxyphenyl)ethylamine; 4-(2-Aminoethyl)catechol; hydroxytyramine; Dopaminum; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)-1,2-benzenediol; 3,4-Dihydroxyphenylethylamine; Dopamina; L-DOPAMINE; ASL 279; Pyrocatechol, 4-(2-aminoethyl)-; 1,2-Benzenediol, 4-(2-aminoethyl)-; Dopaminum [INN-Latin]; Dopamina [INN-Spanish]; Dopamine [INN:BAN]; 3-Hydroxtyramine; alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; KW-3-060; Sinemet; 4-(2-aminoethyl)-pyrocatechol; UNII-VTD58H1Z2X; NSC 173182; a-(3,4-Dihydroxyphenyl)-b-aminoethane; HSDB 3068; 4-(2-Aminoethyl)-1,2-bezenediol; EINECS 200-110-0; VTD58H1Z2X; CHEBI:18243; NSC-173182; LDP; NCGC00015519-05; Pyrocatechol, 4-(2-aminoethyl)- (8CI); DSSTox_CID_2420; 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI); DSSTox_RID_76584; DSSTox_GSID_22420; .alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane; 62-31-7 (HYDROCHLORIDE); CAS-51-61-6; Dopamine (INN); Medopa (TN); NSC169105; Intropin [*hydrochloride*]; 4-(2-Aminoethyl)-1,2-benzenediol hydrochloride; SR-01000075366; .beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; m-Hydroxytyramine-; Dopamine (USAN)(*hydrochloride*); IP 498; Intropin (Salt/Mix); Spectrum_001012; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; CHEMBL59; Spectrum2_001023; Spectrum3_000406; Spectrum4_000525; Spectrum5_000945; Lopac-H-8502; 3- HYDROXYTYRAMINE; Biomol-NT_000001; bmse000909; bmse000933; 3-Hydroxytyramine HCl salt; SCHEMBL8505; 1, 4-(2-aminoethyl)-; Lopac0_000586; Oprea1_088821; BSPBio_001932; GTPL940; KBioGR_001129; KBioGR_002388; KBioGR_002484; KBioSS_001492; KBioSS_002393; KBioSS_002491; cid_65340; BIDD:ER0506; DivK1c_000780; SPECTRUM1505155; SPBio_001205; BPBio1_001123; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; DTXSID6022420; BDBM55121; CTK4E3164; KBio1_000780; KBio2_001492; KBio2_002388; KBio2_002484; KBio2_004060; KBio2_004956; KBio2_005052; KBio2_006628; KBio2_007524; KBio2_007620; KBio3_001152; KBio3_002867; KBio3_002962; ZINC33882; cMAP_000036; cMAP_000065; NINDS_000780; HMS3743I03; BCP34189; Tox21_110167; 2-(3, 4-Dihydroxyphenyl)ethylamine; 2-(3,4-dihydroxyphenyl) ethylamine; ANW-54385; BBL013043; LS-159; NSC173182; SBB004044; STK301601; 3,4-DihydroxyphenylA currencythylamin; AKOS003790978; Tox21_110167_1; CCG-204675; DB00988; FS-5341; MCULE-7558764100; SDCCGSBI-0050568.P005; 2-(3,4-Dihydroxyphenyl)-1-ethanamine; 4-(2-Amino-ethyl)-benzene-1,2-diol; 4-(2-Aminoethyl)-1,2-benzenediol #; IDI1_000780; UPCMLD0ENAT5885989:001; NCGC00015519-01; NCGC00015519-02; NCGC00015519-03; NCGC00015519-04; NCGC00015519-07; NCGC00015519-08; NCGC00015519-09; NCGC00015519-10; NCGC00015519-11; NCGC00096050-01; NCGC00096050-02; NCGC00096050-03; NCGC00096050-04; NCGC00096050-05; AK100905; BP-23276; ST048774; 4-(2-aminoethyl)pyrocatechol;hydrochloride; SBI-0050568.P004; FT-0698513; NS00000608; T7923; 2-(4-Hydroxy-5-oxylatophenyl)-1-ethanaminium; C03758; D07870; 13510-EP2269989A1; 13510-EP2270011A1; 13510-EP2272537A2; 13510-EP2272825A2; 13510-EP2272847A1; 13510-EP2275420A1; 13510-EP2277882A1; 13510-EP2280010A2; 13510-EP2281559A1; 13510-EP2281815A1; 13510-EP2281819A1; 13510-EP2284169A1; 13510-EP2284170A1; 13510-EP2284171A1; 13510-EP2286811A1; 13510-EP2287161A1; 13510-EP2287162A1; 13510-EP2287165A2; 13510-EP2287166A2; 13510-EP2292620A2; 13510-EP2295437A1; 13510-EP2295439A1; 13510-EP2298312A1; 13510-EP2298313A1; 13510-EP2298731A1; 13510-EP2298734A2; 13510-EP2298758A1; 13510-EP2298759A1; 13510-EP2298775A1; 13510-EP2298776A1; 13510-EP2301540A1; 13510-EP2301933A1; 13510-EP2305260A1; 13510-EP2305633A1; 13510-EP2305640A2; 13510-EP2305644A1; 13510-EP2305648A1; 13510-EP2305650A1; 13510-EP2305652A2; 13510-EP2305656A1; 13510-EP2305659A1; 13510-EP2305664A1; 13510-EP2305675A1; 13510-EP2305689A1; 13510-EP2308828A2; 13510-EP2308867A2; 13510-EP2308870A2; 13510-EP2308875A1; 13510-EP2311494A1; 13510-EP2311801A1; 13510-EP2311802A1; 13510-EP2311803A1; 13510-EP2311818A1; 13510-EP2311827A1; 13510-EP2311828A1; 13510-EP2311835A1; 13510-EP2314571A2; 13510-EP2316470A2; 13510-EP2316836A1; 13510-EP2371814A1; 4-(2-azanylethyl)benzene-1,2-diol;hydrochloride; AB00053463-12; AB00053463_13; AB00053463_14; L000232; Q170304; SR-01000075366-7; Oseltamivir-d3;Hydroxytyramin;4-(2-Aminoethyl)benzene-1,2-diol; Dopamine hydrochloride;dopamine hydrochloride;4-(2-aminoethyl)pyrocatechol hydrobromide",
"trade_name": "",
"abbrev_name": "DA",
"description": "catecholamine neurotransmitters; precursor to norepinephrine and epinephrine",
"molecular_formula": "C8H11NO2",
"molecular_weight": "153.18",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "It has been reported that about 80% of the drug is excreted in the urine within 24 hours, primarily as HVA and its sulfate and glucuronide conjugates and as 3,4-dihydroxyphenylacetic acid.\nA very small portion is excreted unchanged.",
"protein_binding": "No information currently available on protein binding.",
"half_life": "2 minutes",
"absorption": "Dopamine is rapidly absorbed from the small intestine.",
"cid": "681",
"classification": "C",
"indications": "",
"side_effects": "",
"atc_codes": "C01CA04",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0401"
],
"references": [
"RC03583"
]
},
{
"compound_ID": "D1286",
"name": "WAY-100635",
"synonyms": "WAY-100635; 162760-96-5; Way 100635; UNII-71IH826FEG; WAY-100,635; CHEMBL31354; cyclohexanecarboxamide, n-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-n-2-pyridinyl-; 71IH826FEG; WAY-100635 maleate; WAY100635; N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide; 634908-75-1; Rec 0/0277; [3H]WAY100635; WAY 100,635; Lopac-W-108; N-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate salt; GTPL80; Lopac0_001229; SCHEMBL84178; GTPL3251; WAY-100635 maleate salt/; BDBM86708; DTXSID20167467; CHEBI:125619; EX-A1053; 2799AH; ABP000343; PDSP1_001716; PDSP2_001699; ZINC52541473; CCG-205303; CS-0418; NSC_104911; SB19513; SDCCGSBI-0051196.P002; N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide; NCGC00016092-01; NCGC00016092-02; NCGC00016092-03; NCGC00016092-13; NCGC00162372-01; AS-74088; HY-10349; LS-56585; WAY 100635;WAY100635; A3933; CAS_146714-97-8; FT-0728251; X7593; W-5217; L000012; Q7946879; n-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-n-2-pyridinyl-cyclohexanecarboxamide; Cyclohexanecarboxamide, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-, hydrochloride; N-[2-[4-(2-METHOXYPHENYL)-1-PIPERAZINYL]ETHYL]-N-2-PYRIDINYL-CYCLOHEXANECARBOXAMIDE TRIHYDROCHLORIDE; N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide-Tritiated",
"trade_name": "",
"abbrev_name": "",
"description": "piperazine drug; selective 5-HT1A receptor antagonist; potent full agonist of D4 receptor",
"molecular_formula": "C25H34N4O2",
"molecular_weight": "422.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5684",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0401"
],
"references": [
"RC03584"
]
},
{
"compound_ID": "D1288",
"name": "8-OH-DPAT",
"synonyms": "8-OH-Dpat; 78950-78-4; 8-Hydroxy-DPAT; 8-HYDROXY-2-(DI-n-PROPYLAMINO)TETRALIN; 7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol; CHEMBL56; C16H25NO; CHEBI:73364; 1-Naphthalenol, 7-(dipropylamino)-5,6,7,8-tetrahydro-; S(-)-8-HYDROXY-DPAT HYDROBROMIDE PARTIAL 5-HT1A SECROT; (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin; (+/-)-8-HYDROXY-2-DIPROPYL-AMINOTETRALIN; 1-Naphthalenol,7-(dipropylamino)-5,6,7,8-tetrahydro-; [3H]-8-OH-DPAT; (+/-)-8-Hydroxy-DPAT hydrobromide; Ro-31-8220 in solution; [3H]8-OH-DPAT; (+-)-8-OH-DPAT; 8-OH-DPAT (8-Hydroxy-DPAT); dl-8-Hydroxy-2-(dipropylamino)tetralin; GTPL7; 8OH-DPAT; Biomol-NT_000095; GTPL31; cid_1220; Lopac0_000576; SCHEMBL496783; BPBio1_001354; 8-Hydroxy-DPAT; 8OH-DPAT; S(-)-8-OH-DPAT HBr; 8-OH-DPAT,(+); 8-OH-DPAT,(-); BDBM21393; CTK5E6257; DTXSID30897384; TQP0825; 8-hydroxy-n,n-dipropylaminotetralin; BCP25681; EX-A2914; S(-)-8-Hydroxy-DPAT hydrobromide; MFCD00153811; PDSP1_000777; PDSP2_000765; CCG-204665; SDCCGSBI-0050558.P002; NCGC00015493-04; NCGC00015493-05; NCGC00015493-06; NCGC00024635-02; NCGC00024635-03; NCGC00024986-02; LS-94994; (+)-8-Hydroxy-2-(dipropylamino)tetralin; DB-018083; DB-108186; HY-112061; CS-0043224; FT-0641759; S8447; L000086; J-007140; Q4644282; SR-01000075571-7; 5,6,7,8-tetrahydro-7-(dipropylamino)-1-naphthalenol; BRD-A48015106-001-01-0; BRD-A48015106-004-03-0; 105558-30-3",
"trade_name": "",
"abbrev_name": "",
"description": "5-HT1A receptor agonist; aminotetralin chemical class",
"molecular_formula": "C16H25NO",
"molecular_weight": "247.38",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "1220",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0401"
],
"references": [
"RC03586"
]
},
{
"compound_ID": "D1289",
"name": "1,3-Dihydro-1-(1-(4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one",
"synonyms": "",
"trade_name": "",
"abbrev_name": "Akt inhibitor VIII",
"description": "selective Akt inhibitor",
"molecular_formula": "C34H29N7O",
"molecular_weight": "551.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "135398501",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0401"
],
"references": [
"RC03587"
]
},
{
"compound_ID": "D1290",
"name": "alpha-4-Dibromoacetophenone",
"synonyms": "",
"trade_name": "",
"abbrev_name": "GSK3beta inhibitor VII",
"description": "GSK3beta inhibitor",
"molecular_formula": "C8H6Br2O",
"molecular_weight": "277.94",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "7454",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0401"
],
"references": [
"RC03588"
]
},
{
"compound_ID": "D1291",
"name": "SKF38393",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "dopamine 1 receptor (D1R) agonist; benzazepine chemical class",
"molecular_formula": "C16H17NO2",
"molecular_weight": "255.31",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "1242",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0401"
],
"references": [
"RC03590"
]
},
{
"compound_ID": "D1292",
"name": "SCH23390",
"synonyms": "7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol",
"trade_name": "",
"abbrev_name": "",
"description": "D1 receptor antagonist ; halobenzazepine",
"molecular_formula": "C21H22ClNO5",
"molecular_weight": "403.9",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "67948733",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0401"
],
"references": [
"RC03592"
]
},
{
"compound_ID": "D1293",
"name": "Amantadine",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "Antiviral",
"molecular_formula": "C10H17N",
"molecular_weight": "151.25",
"state": "solid",
"clearance": "* 0.2 - 0.3 L/hr/kg\n* 0.10 +/- 0.04 L/hr/kg [healthy, elderly male]",
"volume_of_distribution": "* 3 to 8 L/kg [healthy subjects]",
"route_of_elimination": "It is primarily excreted unchanged in the urine by glomerular filtration and tubular secretion.",
"protein_binding": "Approximately 67% bound to plasma proteins over a concentration range of 0.1 to 2.0 µg/mL.",
"half_life": "Mean half-lives ranged from 10 to 14 hours, however renal function impairment causes a severe increase in half life to 7 to 10 days.",
"absorption": "Amantadine is well absorbed orally from the gastrointestinal tract.",
"cid": "2130",
"classification": "N",
"indications": "",
"side_effects": "",
"atc_codes": "N04BB01",
"group": "Drug",
"drug_type": "",
"target": [
"T001",
"T002",
"T408"
],
"function": [
"F0108",
"F0201",
"F0303"
],
"references": [
"RC04023",
"RC04147",
"RC04271",
"RC04395",
"RC04519"
]
},
{
"compound_ID": "D1294",
"name": "Ambroxol",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "Expectorant",
"molecular_formula": "C13H18Br2N2O",
"molecular_weight": "378.1",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "Approximately 90%",
"half_life": "7-12 hours",
"absorption": "Rapid and almost complete.",
"cid": "2132",
"classification": "R",
"indications": "",
"side_effects": "",
"atc_codes": "R05CB06; R03CC63",
"group": "Drug",
"drug_type": "",
"target": [
"T001",
"T002",
"T408"
],
"function": [
"F0108",
"F0201",
"F0303"
],
"references": [
"RC04024",
"RC04148",
"RC04272",
"RC04396",
"RC04520"
]
},
{
"compound_ID": "D1295",
"name": "Amoxicillin",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "Antibiotic",
"molecular_formula": "C16H19N3O5S",
"molecular_weight": "365.4",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "Most of the amoxicillin is excreted unchanged in the urine; its excretion can be delayed by concurrent administration of probenecid.",
"protein_binding": "In blood serum, amoxicillin is approximately 20% protein-bound",
"half_life": "61.3 minutes",
"absorption": "Rapidly absorbed after oral administration.",
"cid": "33613",
"classification": "J; A",
"indications": "",
"side_effects": "",
"atc_codes": "A02BD10; J01CA04; A02BD05; J01CR50; A02BD11; A02BD14; A02BD01; A02BD06; A02BD12; A02BD07; A02BD15; A02BD13; A02BD04; A02BD03",
"group": "Drug",
"drug_type": "",
"target": [
"T408"
],
"function": [
"F0108",
"F0201",
"F0303"
],
"references": [
"RC04026",
"RC04150",
"RC04274",
"RC04398",
"RC04522"
]
},
{
"compound_ID": "D1296",
"name": "Ampicillin",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "Antibiotic",
"molecular_formula": "C16H19N3O4S",
"molecular_weight": "349.4",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "Ampicillin is excreted largely unchanged in the urine.",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "6249",
"classification": "S; J",
"indications": "",
"side_effects": "",
"atc_codes": "J01CA51; J01CR50; J01CA01; S01AA19",
"group": "Drug",
"drug_type": "",
"target": [
"T001",
"T408"
],
"function": [
"F0108",
"F0201",
"F0303"
],
"references": [
"RC04027",
"RC04151",
"RC04275",
"RC04399",
"RC04523"
]
},
{
"compound_ID": "D1297",
"name": "Antipyrine",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "NSAID",
"molecular_formula": "C11H12N2O",
"molecular_weight": "188.23",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "2206",
"classification": "S; N",
"indications": "",
"side_effects": "",
"atc_codes": "S02DA03; N02BB51; N02BB01; N02BB71",
"group": "Drug",
"drug_type": "",
"target": [
"T001",
"T002",
"T408"
],
"function": [
"F0108",
"F0201",
"F0303"
],
"references": [
"RC04028",
"RC04152",
"RC04276",
"RC04400",
"RC04524"
]
},
{
"compound_ID": "D1298",
"name": "Biotin",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "Nutritive agent",
"molecular_formula": "C10H16N2O3S",
"molecular_weight": "244.31",
"state": "solid",
"clearance": "The registered total plasma clearance of atorvastatin is of 625 ml/min.[A19474]",
"volume_of_distribution": "The reported volume of distribution of atorvastatin is of 380 L.[A177397]",
"route_of_elimination": "Atorvastatin is mainly eliminated in the bile without enterohepatic recirculation.[A177397] The renal elimination of atorvastatin is very minimal and represents less than 1% of the eliminated dose.[A19474]",
"protein_binding": "Atorvastatin is highly bound to plasma proteins and over 98% of the administered dose is found in a bound form.[A177397]",
"half_life": "The half-life of atorvastatin is of about 14 hours while the half-life of its metabolites can reach up to 30 hours.[A177397]",
"absorption": "Atorvastatin presents a dose-dependent and non-linear pharmacokinetic profile.[A177436] It is very rapidly absorbed after oral administration. After the administration of a dose of 40 mg, its peak plasma concentration of 28 ng/ml is reached 1-2 hours after initial administration with an AUC of about 200 ng.h/ml.[A177478] It does present a very large first-pass metabolism and hence, its bioavailability is of only 14%.[A177397]\n\nAdministration of atorvastatin with food results in prolonged Tmax and a reduction in Cmax and AUC.[A177415]",
"cid": "171548",
"classification": "C",
"indications": "",
"side_effects": "",
"atc_codes": "C10BX11; C10BX03; C10BX06; C10AA05; C10BX15; C10BX08; C10BX12; C10BA05",
"group": "Drug",
"drug_type": "",
"target": [
"T001",
"T002",
"T408"
],
"function": [
"F0108",
"F0201",
"F0303"
],
"references": [
"RC04030",
"RC04154",
"RC04278",
"RC04402",
"RC04526"
]
},
{
"compound_ID": "D1299",
"name": "lumiracoxib",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "COX-2 selective non-steroidal anti-inflammatory drug (NSAID); analgesics",
"molecular_formula": "C15H13ClFNO2",
"molecular_weight": "293.72",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "151166",
"classification": "A",
"indications": "",
"side_effects": "",
"atc_codes": "A11HA05",
"group": "Drug",
"drug_type": "",
"target": [
"T001",
"T002",
"T408"
],
"function": [
"F0108",
"F0201",
"F021201",
"F0303"
],
"references": [
"RC03614",
"RC04031",
"RC04083",
"RC04155",
"RC04207",
"RC04279",
"RC04331",
"RC04403",
"RC04455",
"RC04527",
"RC04579"
]
},
{
"compound_ID": "D1300",
"name": "mannitol",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "osmotic diuretic that is metabolically inert in humans",
"molecular_formula": "C6H14O6",
"molecular_weight": "182.17",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "It is rapidly excreted in the urine.",
"protein_binding": "None",
"half_life": "100 minutes",
"absorption": "Approximately 7% of ingested mannitol is absorbed during gastrointestinal perfusion in uremic patients.",
"cid": "6251",
"classification": "B; V; A; R",
"indications": "",
"side_effects": "",
"atc_codes": "B05BC01; A06AD16; R05CB16; B05CX04; V04CX04",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0401"
],
"references": [
"RC03595"
]
},
{
"compound_ID": "D1301",
"name": "toxoflavin",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "a toxin produced by a variety of bacteria including Burkholderia gladioli; antibiotic properties; quinoidal-type structural classes",
"molecular_formula": "C7H7N5O2",
"molecular_weight": "193.16",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "66541",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F010501"
],
"references": [
"RC03502"
]
},
{
"compound_ID": "D1302",
"name": "tesimide",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "quinoidal-type structural classes",
"molecular_formula": "C16H15NO2",
"molecular_weight": "253.29",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5384729",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F010501"
],
"references": [
"RC03503"
]
},
{
"compound_ID": "D1303",
"name": "Anthranilic acid ",
"synonyms": "2-aminobenzoic acid",
"trade_name": "",
"abbrev_name": "",
"description": "aromatic acid",
"molecular_formula": "C7H7NO2",
"molecular_weight": "137.14",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "227",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F010701"
],
"references": [
"RC03508"
]
},
{
"compound_ID": "D1304",
"name": "Fluoromethylsulphonanilide ",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [
"F010701"
],
"references": [
"RC03509"
]
},
{
"compound_ID": "D1305",
"name": "Nitrophenol ",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C6H5NO3",
"molecular_weight": "139.11",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "980",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F010701"
],
"references": [
"RC03510"
]
},
{
"compound_ID": "D1306",
"name": "Nitrosulphonanilide ",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [
"F010701"
],
"references": [
"RC03511"
]
},
{
"compound_ID": "D1307",
"name": "Phenylhydrazone ",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [
"F010701"
],
"references": [
"RC03512"
]
},
{
"compound_ID": "D1309",
"name": "Thiadiazinedione ",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [
"F010701"
],
"references": [
"RC03514"
]
},
{
"compound_ID": "D1310",
"name": "Thiazolinedione ",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C3H3NO2S",
"molecular_weight": "117.13",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5437",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F010701"
],
"references": [
"RC03515"
]
},
{
"compound_ID": "D1311",
"name": "Hydronaphthoquinone ",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [
"F0109"
],
"references": [
"RC03516"
]
},
{
"compound_ID": "D1312",
"name": "Naphthoquinone ",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [
"F0109"
],
"references": [
"RC03517",
"RC03523"
]
},
{
"compound_ID": "D1313",
"name": "2‐Anilinobenzoic acid",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C13H11NO2",
"molecular_weight": "213.23",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "4386",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0107"
],
"references": [
"RC03518"
]
},
{
"compound_ID": "D1314",
"name": "2‐(Dialkylamino)‐N‐(2,6‐dimethylphenylacetamide",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C12H18N2O",
"molecular_weight": "206.28",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "89578",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0107"
],
"references": [
"RC03519"
]
},
{
"compound_ID": "D1315",
"name": "Perfluorinated carboxylic acid",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [
"F0107"
],
"references": [
"RC03520"
]
},
{
"compound_ID": "D1316",
"name": "Perfluorinated sulfonamide",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [
"F0107"
],
"references": [
"RC03521"
]
},
{
"compound_ID": "D1317",
"name": "Hydroxynaphthoquinones",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [
"F0109"
],
"references": [
"RC03522"
]
},
{
"compound_ID": "D1318",
"name": "Anthracene‐9,10‐diones",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C28H16O4",
"molecular_weight": "416.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "21275704",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0109"
],
"references": [
"RC03524"
]
},
{
"compound_ID": "D1319",
"name": "Quinones",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [
"F0109"
],
"references": [
"RC03525"
]
},
{
"compound_ID": "D1320",
"name": "Melittin",
"synonyms": "Melittin; Forapin; Honeybee melittin; 20449-79-0; Bee venom melittin; UNII-24VT8NVE75; Forapine; 24VT8NVE75; CHEBI:6736; Melittin (apis cerana); 37231-28-0; GIGAVLKVLTTGLPALISWIKRKRQQ-NH2; Melittin (major) (8CI); CHEMBL412927; MFCD00076868; AKOS024456456; Melittin, >=97% (HPLC), synthetic; RS-2008; NCGC00167171-01; Melittin (GIGAVLKVLTTGLPALISWIKRKRQQ-amide); Melittin from honey bee venom, >=65% (HPLC); Melittin from honey bee venom, >=85% (HPLC); G-I-G-A-V-L-K-V-L-T-T-G-L-P-A-L-I-S-W-I-K-R-K-R-Q-Q-NH2; Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-NH2; Gly-L-Ile-Gly-L-Ala-L-Val-L-Leu-L-Lys-L-Val-L-Leu-L-Thr-L-Thr-Gly-L-Leu-L-Pro-L-Ala-L-Leu-L-Ile-L-Ser-L-Trp-L-Ile-L-Lys-L-Arg-L-Lys-L-Arg-L-Gln-L-Gln-NH2; glycyl-L-isoleucylglycyl-L-alanyl-L-valyl-L-leucyl-L-lysyl-L-valyl-L-leucyl-L-threonyl-L-threonylglycyl-L-leucyl-L-prolyl-L-alanyl-L-leucyl-L-isoleucyl-L-seryl-L-tryptophyl-L-isoleucyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-glutaminyl-L-glutamamide; H-Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-NH2",
"trade_name": "",
"abbrev_name": "",
"description": "26-residue peptide; principal active component of bee venom; powerful anti-inflammatory effect; inhibits the ATPase activity of F1; basic and amphiphilic alpha-helical structures",
"molecular_formula": "C131H229N39O31",
"molecular_weight": "2846.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "16133648",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F021201"
],
"references": [
"RC01227"
]
},
{
"compound_ID": "D1321",
"name": "IF1",
"synonyms": "inhibitor protein",
"trade_name": "",
"abbrev_name": "IF1",
"description": "natural regulatory peptide of 56 to 87 residues found in mitochondria",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [
"F021204"
],
"references": [
"RC01228",
"RC01229",
"RC01230",
"RC01231",
"RC01232",
"RC01233"
]
},
{
"compound_ID": "D1322",
"name": "Angiostatin",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "57-kDa N-terminal fragment of a larger protein, plasmin, which is also a fragment of plasminogen; natural angiogenesis inhibitor",
"molecular_formula": "X",
"molecular_weight": "X",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "X",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Others",
"drug_type": "",
"target": [],
"function": [
"F021204"
],
"references": [
"RC01234"
]
},
{
"compound_ID": "D1323",
"name": "Enterostatin",
"synonyms": "Enterostatin; APGPR Enterostatin; APGPR; 117830-79-2; Ala-pro-gly-pro-arg; Procolipase activation peptide; Enterostatin(human,mouse,rat); Enterostatin(human); Enterostatin[human]; L-alanyl-L-prolylglycyl-L-prolyl-L-Arginine; ENTEROSTATIN, HUMAN; Enterostatin human; CLAP; Alanyl-prolyl-glycyl-prolyl-arginine; Ala-Pro-Asp-Pro-Arg; H-Ala-Pro-Gly-Pro-Arg-OH; CHEBI:89430; DTXSID20151927; Enterostatin (human, mouse, rat); HY-P1067; ZINC15721425; Enterostatin human, >=97% (HPLC); AKOS024457717; CS-0026705; Q5380242; N2-[1-[N-(1-L-alanyl-L-prolyl)glycyl]-L-prolyl] L-Arginine; L-Arginine, N2-(1-(N-(1-L-alanyl-L-prolyl)glycyl)-L-prolyl)-; (2S)-2-{[(2S)-1-(2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}acetyl)pyrrolidin-2-yl]formamido}-5-[(diaminomethylidene)amino]pentanoic acid; (S)-2-((S)-1-(2-((S)-1-((S)-2-aminopropanoyl)pyrrolidine-2-carboxamido)acetyl)pyrrolidine-2-carboxamido)-5-guanidinopentanoic acid",
"trade_name": "",
"abbrev_name": "",
"description": "pentapeptide released from procolipase during dietary fat digestion",
"molecular_formula": "C21H36N8O6",
"molecular_weight": "496.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "3082883",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T019003003"
],
"function": [
"F021201"
],
"references": [
"RC01235"
]
},
{
"compound_ID": "D1324",
"name": "ethyldimethylaminopropyl carbodiimide",
"synonyms": "1892-57-5; 1-(3-DIMETHYLAMINOPROPYL)-3-ETHYLCARBODIIMIDE; N1-((Ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine; 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide; EDAC; UNII-RJ5OZG6I4A; EDCI; 1-Ethyl-3-(3-(dimethylamino)propyl)carbodiimide; 1,3-Propanediamine, N'-(ethylcarbonimidoyl)-N,N-dimethyl-; N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide; RJ5OZG6I4A; ETHYLDIMETHYLAMINOPROPYL CARBODIIMIDE; 1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide; N-[3-(Dimethylamino)propyl]-N'-ethylcarbodiimide; ethyl dimethylaminopropyl carbodiimide; N'-(Ethylcarbonimidoyl)-N,N-dimethylpropane-1,3-diamine; ({[3-(dimethylamino)propyl]imino}methylidene)(ethyl)amine; AK-77427; (3-(Dimethylamino)propyl)ethylcarbodiimide; [3-(Dimethylamino)propyl]ethylcarbodiimide; 1-ethyl-3(3-dimethylaminopropyl)carbodiimide; N'-(3-dimethylaminopropyl)-N-ethylcarbodiimide; N-Ethyl-N'-(3-dimethylaminopropyl)carbodiimide; EDC.HCl; 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide; 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide; 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide; J-503137; J-670018; 1,3-Propanediamine, N3-(ethylcarbonimidoyl)-N1,N1-dimethyl-; (3-dimethylaminopropyl)ethyl carbodiimide; NSC97064; NSC-97064; 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide; 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide; 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide; N-(3-(dimethylamino)propyl)-N'-ethylcarbodiimide; N-ethyl-N'-[3-(dimethylamino)propyl]carbodiimide; N-ethyl-N'-{3-(dimethylamino)propyl}carbodiimide; 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide, 97%; wsci; C8H17N3; EINECS 217-579-2; 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydrochloride; 3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine; ACMC-209esd; 1-ethyl-3-(N; SCHEMBL1372; NCIStruc1_000086; NCIStruc2_000020; SCHEMBL2645828; CHEMBL1397523; CTK3J6950; KS-00001PQK; 3-(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine; DTXSID60865258; dimethylaminopropylethylcarbodiimide; ethyl dimethylaminopropylcarbodiimide; KS-00000FC1; NCI97064; ZINC8034743; ANW-23435; CCG-36290; dimethylaminopropyl ethyl carbodiimide; MFCD00044916; NCGC00014011; SBB056492; STL183833; (dimethylaminopropyl)ethyl carbodiimide; AKOS009031335; CS-W022912; MCULE-5755938583; (3-dimethylaminopropyl)ethylcarbodiimide; ethyl(3-dimethylaminopropyl)carbodiimide; ethyl-(dimethylaminopropyl) carbodiimide; (3-dimethylaminopropyl)-ethylcarbodiimide; 1-ethyl-3-dimethylaminopropylcarbodiimide; 3-dimethylaminopropyl-3-ethylcarbodiimide; ethyl 3-(dimethylamino)propylcarbodiimide; ethyl(3'-dimethylaminopropyl)carbodiimide; ethyl-(3-dimethylaminopropyl)carbodiimide; NCGC00014011-02; NCGC00097120-01; Water soluble carbodiimide, Free of salt; (4,6-diazaocta-4,5-dienyl)dimethylamine; AS-54294; CC-04475; N-dimethylaminopropyl-N'-ethylcarbodiimide; N-Ethyl-N'-dimethylaminopropylcarbodiimide; N096; NCI60_042168; SC-19667; (3-dimethylaminopropyl)-ethyl carbodiimide; (3-dimethylaminopropyl)-ethyl-carbodiimide; 1-ethyl-3-dimethylaminopropyl carbodiimide; ethyl-(3'-dimethylaminopropyl)carbodiimide; n-ethyl-n'(dimethylaminopropyl)carbodiimide; (3-(dimethylamino)propyl)ethyl carbodiimide; (3-dimethylamino-propyl)-ethyl-carbodiimide; 1(3-dimethylaminopropyl)3-ethylcarbodiimide; 1-(dimethylaminopropyl)-3-ethylcarbodiimide; 1-ethyl-3-(dimethylaminopropyl)carbodiimide; 3-(dimethylamino)propyl-3-ethylcarbodiimide; DB-044701; ethyl 3(3' dimethylaminopropyl)carbodiimide; ethyl-1-(3-dimethylaminopropyl)carbodiimide; Ethyl-3-(3-dimethylaminopropyl)carbodiimide; N-(3-dimethylaminopropyl)-ethylcarbodiimide; N-ethyl-N'-dimethylaminopropyl carbodiimide; N-ethyl-N'-dimethylaminopropyl-carbodiimide; 1 -ethyl-(3-dimethylaminopropyl)carbodiimide; 1(3-dimethylaminopropyl)-3-ethylcarbodiimide; 1-(3dimethylaminopropyl)-3ethyl carbodiimide; 1-ethyl-3-(3dimethylaminopropyl)carbodiimide; 1-ethyl-3-(dimethylaminopropyl) carbodiimide; 1-ethyl-3-(dimethylaminopropyl)-carbodiimide; D4029; ethyl-[3-(dimethylamino)propyl]-carbodiimide; ethyl-3-(3 dimethylaminopropyl)-carbodiimide; FT-0605621; N-(Dimethylaminopropyl)-N'-ethylcarbodiimide; n-ethyl-n'-(dimethylaminopropyl)carbodiimide; NS00015301; 1-(3-dimethlaminopropyl)-3-ethylcarbodiimide; 1-(3-dimethylaminopropyl)-3-ehtylcarbodiimide; 1-(3-dimethylaminopropyl)-3-ethylcarbodimide; 1-(3-dimethylaminopropyl)-3ethyl carbodiimide; 1-(3-dimethylaminopropyl)-3ethyl-carbodiimide; 1-(ethyl)-3-(dimethylaminopropyl)carbodiimide; 1-[3(dimethylamino)propyl]3-ethylcarbodiimide; 1-ethly-3-(3-dimethylaminopropyl)carbodiimide; 1-ethyl 3-(3-dimethylaminopropyl)carbodiimide; 1-ethyl-3-(3'dimethylaminopropyl)carbodiimide; 1-ethyl-3-(3-dimethylaminopropyl)carbodimide; 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide; Ethyl-(N',N'-dimethylamino)propylcarbodiimide; n'-(3-dimethylaminopropyl)-n-ethylcarbodiimid; N-(3-dimethylaminopropyl)-3-ethylcarbodiimide; N-(3-dimethylaminopropyl)-N'-ethylcarbodimide; N-(3-dimethylaminopropyl)-N'ethylcarbodiimide; N-ethyl-N'-(dimethylaminopropyl)-carbodiimide; 1-(3 dimethylaminopropyl)-3-ethyl carbodiimide; 1-(3--dimethylaminopropyl)-3-ethylcarbodiimide; 1-(3-dimethylamino-propyl)-3-ethylcarbodiimide; 1-(3-dimethylaminopropyl )-3-ethylcarbodiimide; 1-(3-dimethylaminopropyl) -3-ethylcarbodiimide; 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide; 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide; 1-(ethyl)-3-(dimethylaminopropyl) carbodiimide; 1-[3-(dimethylamino)propyl]3-ethylcarbodiimide; 1-ethyl-3-(3'-dimethylaminopropyl)carbodimide; 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide; 1-ethyl-3-(3-dimethylaminopropyl) carbodimide; 3-(3'-dimethylaminopropyl)-1-ethylcarbodiimide; 6590-EP1441224A2; N-(3-dimethylaminopropyl)-N' ethylcarbodiimide; n-(3-dimethylaminopropyl)-n'-ethyl-carbodiimid; 1-(3-dimethanylaminopropyl)-3-ethylcarbodiimide; 1-(3-dimethyl aminopropyl)-3-ethyl carbodiimide; 1-(3-Dimethylamino-propyl)-3-ethyl-carbodiimide; 1-[3-(dimethylamino)propyl]-3 ethylcarbodiimide; 1-ethyl 3-(3-dimethylamino-propyl)-carbodiimide; 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide; 1-ethyl-3-(3'-dimethylamino-propyl)carbodiimide; 1-ethyl-3-(3'-dimethylaminopropyl) carbodiimide; 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide; 1-ethyl-3-(3'-dimethylaminopropyl)-carbodimide; 11132-EP2272830A1; 11132-EP2289890A1; 11132-EP2295402A2; 11132-EP2295439A1; 11132-EP2301934A1; 11132-EP2305643A1; 11132-EP2316827A1; 11132-EP2377849A2; 11136-EP2316825A1; 11136-EP2316827A1; 11146-EP2269610A2; 11146-EP2270004A1; 11146-EP2275411A2; 11146-EP2298747A1; 11146-EP2301922A1; 11146-EP2305641A1; 11146-EP2308846A2; 11146-EP2308851A1; 11146-EP2311806A2; 11146-EP2311840A1; 11146-EP2316458A1; 11146-EP2316827A1; 11146-EP2316828A1; 13197-EP2269977A2; 13197-EP2275102A1; 13197-EP2275105A1; 13197-EP2277867A2; 13197-EP2280003A2; 13197-EP2280012A2; 13197-EP2281813A1; 13197-EP2281819A1; 13197-EP2284157A1; 13197-EP2284159A1; 13197-EP2284171A1; 13197-EP2286811A1; 13197-EP2289893A1; 13197-EP2289894A2; 13197-EP2292228A1; 13197-EP2292625A1; 13197-EP2295053A1; 13197-EP2295401A2; 13197-EP2295402A2; 13197-EP2295406A1; 13197-EP2295407A1; 13197-EP2295410A1; 13197-EP2295426A1; 13197-EP2295427A1; 13197-EP2295439A1; 13197-EP2298736A1; 13197-EP2298743A1; 13197-EP2298744A2; 13197-EP2298761A1; 13197-EP2298779A1; 13197-EP2301923A1; 13197-EP2301939A1; 13197-EP2305667A2; 13197-EP2305671A1; 13197-EP2305675A1; 13197-EP2308812A2; 13197-EP2308833A2; 13197-EP2308840A1; 13197-EP2311830A1; 13197-EP2311842A2; 13197-EP2314295A1; 13197-EP2316832A1; 13197-EP2316833A1; 13197-EP2316834A1; 14973-EP2269610A2; 14973-EP2269990A1; 14973-EP2275421A1; 14973-EP2280000A1; 14973-EP2284171A1; 14973-EP2289510A1; 14973-EP2289887A2; 14973-EP2289888A2; 14973-EP2298778A1; 14973-EP2305808A1; 14973-EP2308828A2; 14973-EP2308838A1; 14973-EP2308873A1; 14973-EP2308877A1; 14973-EP2311811A1; 14973-EP2314295A1; 14973-EP2314585A1; 14973-EP2316457A1; 14973-EP2316458A1; 20582-EP2305647A1; 20582-EP2308869A1; 20582-EP2314585A1; 3-(3'-dimethylaminopropyl)-1-ethyl carbodiimide; 3-ethyl-1-(3-(dimethylamino)propyl)carbodiimide; 42417-EP2272517A1; 42417-EP2272825A2; 42417-EP2272834A1; 42417-EP2289894A2; 42417-EP2292228A1; 42417-EP2301929A1; 42417-EP2301935A1; 42417-EP2305674A1; 42417-EP2311808A1; 42417-EP2311829A1; 58902-EP2277878A1; 58902-EP2298772A1; 58902-EP2305682A1; 58902-EP2308839A1; 58902-EP2308879A1; 76079-EP2308842A1; 85252-EP2272537A2; 85252-EP2289887A2; 85252-EP2289888A2; 85252-EP2305808A1; N'-(3-dimethylaminopropyl)-N-ethyl-carbodiimide; N-(-3-dimethylaminopropyl)-N'-ethylcarbodiimide; N-(3-dimethylamino-propyl)-N'-ethylcarbodiimide; N-(3-dimethylaminopropyl)-N'-ethyl carbodiimide; N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide; N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide; 1-(3-(dimethylamino)-propyl)-3-ethylcarbodiimide; 1-(3-dimethylaminoprop-1-yl)-3-ethylcarbodiimide; 1-[3-(dimethylamino) propyl]-3-ethylcarbodiimide; 1-[3-(dimethylamino)propyl]-3-ethyl carbodiimide; 1-ethyl-3-(3-(dimethylamino)-propyl)carbodiimide; 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide; 113545-EP2281820A2; 113545-EP2298754A1; 139879-EP2292628A2; 952D538; C-03453; Q161622; 1-ethyl-3-(3-(dimethylamino)-propyl) carbodiimide; 1-ethyl-3-[3'-(dimethylamino)propyl]-carbodiimide; 1-ethyl-3-[3-(dimethylamino)propyl]-carbodi-imide; N-[3-(Dimethylamino)propyl]-N'-ethylcarbodiimide #; N-ethyl-N'-3-(N,N-dimethylamino)propylcarbodiimide; 1-ethyl-3-[3-(N,N-dimethylamino)propyl]carbodiimide; ({[3-(dimethylamino)propyl]iminomethylidene)(ethyl)amine; N3-Ethyliminomethylene-N1,N1-dimethylpropane-1,3-diamine; N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide, >=97.0% (T); N-Ethyl-N'-(3-dimethylaminopropyl)carbodiimide C8H17N3 155.24 0.885 66-68 degrees /1mm >110 degrees (230 degrees F) 1.4610 1892-57-5 217-579-2 MFCD00044916 UN2735 8 Y",
"trade_name": "",
"abbrev_name": "EDC",
"description": "water-soluble carbodiimides",
"molecular_formula": "C8H17N3",
"molecular_weight": "155.24",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "15908",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T019003004"
],
"function": [
"F021201"
],
"references": [
"RC01236"
]
},
{
"compound_ID": "D1325",
"name": "1,5-difluoro-2,4-dinitrobenzene",
"synonyms": "1,5-Difluoro-2,4-dinitrobenzene; 327-92-4; 1,3-Difluoro-4,6-dinitrobenzene; Benzene, 1,5-difluoro-2,4-dinitro-; DFDNB; FFDNB; 4,6-Difluoro-1,3-dinitrobenzene; UNII-G5VV4MQ22V; EINECS 206-324-0; NSC 10246; G5VV4MQ22V; 2,4-difluoro-1,5-dinitrobenzene; 1,3-Dinitro-4,6-difluorobenzene; C6H2F2N2O4; PubChem4398; ACMC-1CLI3; SCHEMBL45486; KSC490O1B; DTXSID6059813; SCHEMBL18934671; SCHEMBL18934796; CTK3J0710; 1,5-dinitro-2,4-difluorobenzene; 2,4-Dinitro-1,5-difluorobenzene; Benzene,5-difluoro-2,4-dinitro-; ACT12642; KS-00000V5I; NSC10246; ZINC1706147; ANW-27448; LABOTEST-BB LT00159520; LABOTEST-BB LT03380744; MFCD00007052; NSC-10246; SBB057211; 4,6-DIFLUORO-M-DINITROBENZENE; AKOS000121134; AC-9710; AM61902; AS01569; Benzene, 1,3-difluoro-4,6-dinitro-; CM12219; GS-3137; MCULE-3968160378; NE10469; PF10287; VZ20736; 1,5-Difluoro-2,4-dinitrobenzene, 97%; I112; LS-29837; DB-048267; D1649; FT-0606957; NS00041863; ST50308249; A20578; J-018878; Q27278804; 2,4-Dinitro-1,5-difluorobenzene;2,6-dinitro-3,5-difluorobenzene;4,6-Difluoro-1,3-dinitrobenzene",
"trade_name": "",
"abbrev_name": "DFDNB",
"description": "",
"molecular_formula": "C6H2F2N2O4",
"molecular_weight": "204.09",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "67598",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T019003"
],
"function": [
"F021201"
],
"references": [
"RC01237"
]
},
{
"compound_ID": "D1326",
"name": "N-ethylmaleimide",
"synonyms": "N-ethylmaleimide; 128-53-0; 1-Ethyl-1H-pyrrole-2,5-dione; ethylmaleimide; 1H-pyrrole-2,5-dione, 1-ethyl-; maleimide, N-ethyl-; NEM; maleic acid N-ethylimide; USAF B-121; 1-ethylpyrrole-2,5-dione; UNII-O3C74ACM9V; NSC 7638; EINECS 204-892-4; MFCD00005509; BRN 0112448; CHEMBL8211; O3C74ACM9V; AI3-50085; CHEBI:44485; N-Ethylmaleimide, 99+%; 25668-22-8; n-ethylmaleimide (nem); N-EM; Lopac-E-3876; ACMC-209bf8; 1-ethylazoline-2,5-dione; WLN: T5VNVJ B2; 1H-Pyrrole-2, 1-ethyl-; Lopac0_000492; SCHEMBL19666; KBioGR_002548; KBioSS_002557; 5-21-10-00006 (Beilstein Handbook Reference); Maleimide, N-ethyl- (8CI); GTPL5335; SCHEMBL9359266; DTXSID1059573; CTK1A6181; KBio2_002548; KBio2_005116; KBio2_007684; KBio3_003026; KS-00000GSO; NSC7638; cMAP_000078; Bio1_000439; Bio1_000928; Bio1_001417; HMS3261D05; ZINC901367; 1-Ethyl-1H-Pyrrole-2, 5-dione; 1-ethyl-3-pyrroline-2,5-quinone; EBD21453; HY-D0843; NSC-7638; NSC92547; 1-Ethyl-1H-pyrrole-2,5-dione #; Tox21_500492; 7671AF; ANW-19074; BDBM50220832; GEO-01358; HSCI1_000382; NSC-92547; PI-149; s3692; STK802307; AKOS000249392; AKOS025244114; CCG-204583; DB02967; FS-4064; LP00492; LS41520; MCULE-9216989340; SDCCGSBI-0050476.P003; NCGC00015415-01; NCGC00015415-02; NCGC00015415-03; NCGC00015415-04; NCGC00093895-01; NCGC00093895-02; NCGC00261177-01; AK-47781; 1-ETHYL-1H-PYRROLE-2,5-DIONENEM; DB-041899; LS-136944; 1-ethyl-2,5-dihydro-1H-pyrrole-2,5-dione; CS-0014814; E0136; EU-0100492; FT-0631750; N-Ethylmaleimide, BioXtra, >=98% (HPLC); NS00024051; ST51037241; C02441; E 3876; E-8100; N-Ethylmaleimide, crystalline, >=98% (HPLC); N-Ethylmaleimide, BioUltra, >=99.0% (HPLC); Q292393; SR-01000075860; N-Ethylmaleimide, purum p.a., >=99.0% (HPLC); SR-01000075860-1; BRD-K98297262-001-01-1; 4D028806-9A8A-4D25-B355-AEFDEC5AD901; F0001-0396",
"trade_name": "",
"abbrev_name": "NEM",
"description": "Thiol group reagents",
"molecular_formula": "C6H7NO2",
"molecular_weight": "125.13",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "4362",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [
"T214"
],
"function": [
"F02110308"
],
"references": [
"RC01241"
]
},
{
"compound_ID": "D1327",
"name": "NBD-Cl",
"synonyms": "4-Chloro-7-nitrobenzofurazan; 10199-89-0; Nbd chloride; 4-Chloro-7-nitro-2,1,3-benzoxadiazole; 4-Chloro-7-nitrobenzo-2-oxa-1,3-diazole; NBD-Cl; 2,1,3-Benzoxadiazole, 4-chloro-7-nitro-; NBD-chloride; 7-Chloro-4-nitrobenzofurazan; 1-Chloro-4-nitrobenzoxadiazole; NBD-C 1; 4-Nitro-7-chlorobenzofurazan; 7-Chloro-4-nitrobenzo-2-oxa-1,3-diazole; BENZOFURAZAN, 4-CHLORO-7-NITRO-; 4-Chloro-7-nitrobenzo[c][1,2,5]oxadiazole; UNII-EQF2794IRE; NSC 228140; NBF-Cl; Chloronitrobenzoxadiazole; EINECS 233-496-4; C6H2ClN3O3; BRN 0614212; EQF2794IRE; 4-chloro-7-nitrobenzo-2,1,3-oxadiazole; CHEBI:78878; NBD chloride, 98%; 4-chloro-7-nitrobenzo[c]1,2,5-oxadiazole; MFCD00005808; Shokat-update-comp17; nchembio866-comp17; Nitrobenzoxadiazole Chloride; 4-CHLORO-7-NITROBENZ-2-OXA-1,3-DIAZOLE; SCHEMBL41754; 7-Nitro-4-chlorobenzofurazan; 4-Chloro-7-nitrobenzofurazane; 4-chloro-7-nitro-benzofurazan; 7-chloro-4-nitro-benzofurazan; AMBZ0375; CHEMBL1743207; DTXSID2064995; SCHEMBL16305393; CTK8E4966; ALBB-020690; HY-D0042; ZINC1311094; 4-Chloro-7-nitrobenzofurazan, 98%; BBL011971; NSC228140; SBB005345; STK728793; AKOS000121286; ACN-048974; AM85450; CS-7530; MCULE-4610896893; NSC-228140; QC-1844; 4-Chloro-7-nitro-benzoxa[1,3]diazole; UPCMLD0ENAT5654999:001; 4-chloro-7-nitro 2,1,3-benzoxadiazole; AC-24649; AS-64042; LS-35358; ST033521; 4-Chloro-7-nitro-2,1,3-benzoxadiazole #; EU-0033246; FT-0618144; NS00023098; 4-Chloro-7-nitro-benzo[c][1,2,5]oxadiazole; 199C890; 4-CHLORO-7-NITRO-BENZO[1,2,5]OXADIAZOLE; 7-CHLORO-4-NITROBENZ-2-OXA-1,3-DIAZOLE; Q229939; SR-01000596972; J-100055; J-610037; SR-01000596972-1; 4-Chloro-7-nitrobenzofurazan, BioReagent, suitable for fluorescence, >=97.0% (HPLC)",
"trade_name": "",
"abbrev_name": "",
"description": "fluorescent adenine analog that labels Tyr or Cys residues",
"molecular_formula": "C6H2ClN3O3",
"molecular_weight": "199.55",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "25043",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T019003"
],
"function": [
"F021201",
"F021204"
],
"references": [
"RC01238",
"RC01239"
]
},
{
"compound_ID": "D1328",
"name": "Mersalyl",
"synonyms": "Mersalyl acid; Mersalyl; 486-67-9; NCGC00181320-01; Mersal; DSSTox_CID_26902; DSSTox_RID_82001; DSSTox_GSID_46902; SCHEMBL993248; CHEBI:6771; GTPL5331; DTXSID3046902; Mersalyl acid, analytical standard; Tox21_112788; ACM486679; API0003303; DB09338; CAS-486-67-9; C11336; C-33804; Q424871; (3-(2-(carboxymethoxy)benzamido)-2-methoxypropyl)(hydroxy)mercury; Mercurate(1-), [3-[[2-(carboxylatomethoxy)benzoyl]amino]-2-methoxypropyl]hydroxy-, hydrogen",
"trade_name": "",
"abbrev_name": "",
"description": "Thiol group reagents",
"molecular_formula": "C13H18HgNO6",
"molecular_weight": "484.88",
"state": "solid",
"clearance": "The hepatobiliary excretion of mersayl was studied in the isolated perfused rat liver and in isolated rat liver plasma membrane vesicles. In the isolated perfused liver, mersalyl was found to be immediately absorbed by the perfusion medium and concentratively excreted into bile. Uptake is characterized by saturation kinetics (S)0.5 = 20 microM, Vmax = 117 nmoles/min/g liver, cooperatively of mersalyl binding sites, stimulation by extracellular sodium and temperature dependence. Uptake of mersalyl into basolateral membrane vesicles also demonstrates characteristics of a carrier-mediated transport, dependence on extravesicular sodium, cooperativity of mersalyl binding sites, temperature dependence and trans-stimulation by intravesicular non-radioactive mersalyl. Uptake was found to be inhibited by alpha-naphthylacetic acid and mercapto group reagents, suggesting involvement of mercapto groups on the carrier and a binding site for carboxylic anions. Data from the isolated perfused liver and from isolated basolateral vesicles suggest that mersalyl uptake into the liver is carrier mediated. Uptake mechanism and driving forces appear analogous to those for the uptake of chemically related compounds such as taurocholic acid. It is, therefore, speculated that mersalyl may be transported by carrier molecules which accept various chemically unrelated compounds [L1584].",
"volume_of_distribution": "",
"route_of_elimination": "Organic mercury is metabolized into inorganic mercury, which is eventually excreted in the urine and feces [L1582].",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "443130",
"classification": "C",
"indications": "",
"side_effects": "",
"atc_codes": "C03BC01",
"group": "Drug",
"drug_type": "",
"target": [
"T019002",
"T214"
],
"function": [
"F0110"
],
"references": [
"RC01242",
"RC01243"
]
},
{
"compound_ID": "D1329",
"name": "diamide",
"synonyms": "DIAMIDE; N,N,N',N'-Tetramethylazodicarboxamide; TMAD; 10465-78-8; Tetramethyldiazenedicarboxamide; 1,1'-Azobis(N,N-dimethylformamide); Diazenedicarboxamide, tetramethyl-; N,N,N',N'-Tetramethylazoformamide; Diazenedicarboxylic acid bis(N,N-dimethylamide); N,N,N',N'-Tetramethylazobisformamide; Azodicarboxylic acid bis-dimethylamide; N1,N1,N2,N2-Tetramethyldiazene-1,2-dicarboxamide; 3-(N,N-Dimethylcarbamoylimido)-1,1-dimethylurea; Tetramethylazodicarboxamide; NSC 143013; UNII-86EQC90W32; N,N,N',N'-Tetramethylazodicarboxamide(TMAD); EINECS 233-951-7; A 19315; BRN 1910409; Formamide, 1,1'-azobis(N,N-dimethyl-; AI3-61614; CHEBI:48963; 86EQC90W32; NSC143013; N,N,N',N'-tetramethyldiazene-1,2-dicarboxamide; 1,1'-Azobis(N,N-dimethylformamide), 98%; CHEBI:48958; N,N',N'-Tetramethylazodicarboxamide; (E)-1,1'-azobis(N,N-dimethylformamide); Azodicarboxylic acid bis(dimethylamide); 1,N-dimethylformamide); SCHEMBL39340; (3E)-3-(dimethylcarbamoylimino)-1,1-dimethyl-urea; (E)-1-[(dimethylcarbamoyl)imino]-3,3-dimethylurea; CHEMBL1255835; N,N',N'-Tetramethylazoformamide; HMS3261O15; N,N',N'-Tetramethylazobisformamide; ACN-S004394; EBD53505; Formamide,1'-azobis[N,N-dimethyl-; Tox21_500397; 1040AA; AKOS006230755; CCG-204490; CS-W019102; diazenedicarboxylic acid bis-methylamide; GS-5526; NSC-143013; SDCCGSBI-0050383.P002; 1,1'-Azobis (N,N-dimethyl formamide); NCGC00093824-01; NCGC00093824-02; NCGC00093824-03; NCGC00261082-01; BP-10037; Diazenedicarboxamide, tetramethyl- (9CI); LS-69428; SC-24561; AB0069798; EU-0100397; NS00023310; D 3648; K-0427; Azodicarboxylic acid bis(dimethylamide); diamide; 465D788; C-31377; SR-01000075812; J-001215; SR-01000075812-1; (1E)-1-(dimethyl-carbamoylimino)-3,3-dimethyl-urea; (E)-N,N,N',N'-tetramethyldiazene-1,2-dicarboxamide; (3E)-3-(Dimethylcarbamoylimino)-1,1-dimethyl-urea, 97%",
"trade_name": "",
"abbrev_name": "",
"description": "a dithiol oxidant which oxidizes and crosslinks intracellular thiols such as GSH and protein cysteines",
"molecular_formula": "C6H12N4O2",
"molecular_weight": "172.19",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5353800",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T386"
],
"function": [],
"references": [
"RC01244"
]
}
]
}
